U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL
NATIONAL INSTITUTE FOR OCCUPATIONAL
SAFETY AND HEALTH

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

WORK GROUP ON WELDON SPRING PLANT

+ + + + +

TUESDAY
OCTOBER 19, 2010

+ + + + +

The Work Group convened in the Cincinnati Room of the Cincinnati Airport Marriott, 2395 Progress Drive, Hebron, Kentucky, at 9:00 a.m., Michael H. Gibson, Chairman, presiding.

PRESENT:

MICHAEL H. GIBSON, Chairman RICHARD LEMEN, Member* ROBERT W. PRESLEY, Member

ALSO PRESENT:

TED KATZ, Designated Federal Official NANCY ADAMS, NIOSH Contractor RON BUCHANAN, SC&A MEL CHEW, ORAU Team JOE FITZGERALD, SC&A DAVE HARRISON, ORAU Team MONICA HARRISON-MAPLES, ORAU Team STU HINNEFELD, DCAS EMILY HOWELL, HHS KAREN JOHNSON, Weldon Spring Petitioner MARY JOHNSON JENNY LIN, HHS* ARJUN MAKHIJANI, SC&A JOHN MAURO, SC&A* ROBERT MORRIS, ORAU Team MARK ROLFES, DCAS TINA TRIPLET, Weldon Spring Petitioner

^{*}Participating via telephone

C-O-N-T-E-N-T-S

Welcome and Introduction4
Overview of Weldon Spring Site Evaluation Report and SEC Status9
Issues Matrix for Weldon Spring Site Evaluation Report and SEC Petition12
Draft NIOSH Response to SCA Issues Matrix174
Administrative Detail and Calendar 205

1	P-R-O-C-E-E-D-I-N-G-S
2	(9:02 a.m.)
3	MR. KATZ: So good morning,
4	everyone in the room and on the line.
5	This is Ted Katz with the Advisory
6	Board on Radiation and Worker Health. This is
7	the Weldon Spring Work Group. I'm the
8	Designated Federal Official for the Advisory
9	Board. And we're going to get started in a
10	minute.
11	Before we go on record, we're
12	going to do roll call. And let's begin with
13	Board Members in the room with the Chair.
14	CHAIRMAN GIBSON: Mike Gibson,
15	Chair of the Weldon Spring Work Group.
16	MR. KATZ: And please speak to
17	conflict.
18	CHAIRMAN GIBSON: No conflicts.
19	MEMBER PRESLEY: Robert Presley,
20	Board Member. No conflict.

- 1 MR. KATZ: And on the line, Board
- 2 Members?
- 3 MEMBER LEMEN: Richard Lemen. No
- 4 conflict.
- 5 MR. KATZ: Welcome, Richard --
- 6 Dick.
- 7 Okay. And now NIOSH ORAU Team in
- 8 the room?
- 9 MR. HINNEFELD: Stu Hinnefeld,
- 10 Interim Director of DCAS.
- 11 MR. ROLFES: Mark Rolfes, health
- 12 physicist with DCAS. No conflict of interest.
- 13 MR. HINNEFELD: Yes. No conflict
- on my part, either.
- MR. KATZ: Any NIOSH ORAU Team on
- 16 the line?
- 17 DR. CHEW: Mel Chew, ORAU Team.
- 18 No conflict.
- MR. KATZ: Welcome, Mel.
- 20 MR. MORRIS: Robert Morris.
- 21 MS. HARRISON-MAPLES: Monica

- 1 Harrison-Maples, ORAU Team. No conflict.
- MR. KATZ: Okay. So we have
- 3 Robert Morris and Monica --
- 4 MS. HARRISON-MAPLES: Harrison-
- 5 Maples.
- 6 MR. KATZ: Harrison-Maples. I
- 7 always get those switched around. But thank
- 8 you.
- 9 MS. HARRISON-MAPLES: That's okay.
- 10 MR. KATZ: And both of those, no
- 11 conflict?
- 12 MR. MORRIS: No conflict for
- 13 Robert.
- 14 MR. KATZ: Right. SC&A in the
- 15 room?
- MR. FITZGERALD: Joe Fitzgerald.
- 17 No conflict.
- 18 DR. BUCHANAN: Ron Buchanan. No
- 19 conflict with Weldon Spring.
- 20 DR. MAKHIJANI: Arjun Makhijani.
- 21 No conflict.

- 1 MR. KATZ: And SC&A on the line?
- DR. MAURO: John Mauro, SC&A. No
- 3 conflict.
- 4 MR. KATZ: Welcome, John.
- 5 Very good. And federal officials
- or contractors for the feds in HHS and other
- 7 agencies in the room?
- MS. HOWELL: Emily Howell, HHS.
- 9 MR. KATZ: And on the line?
- 10 MS. LIN: Jenny Lin, HHS.
- 11 MS. ADAMS: Nancy Adams, NIOSH
- 12 contractor.
- MR. KATZ: Welcome, Jenny and
- 14 Nancy.
- 15 MR. HARRISON: This is Dave
- 16 Harrison, ORAU Team with no conflict.
- 17 MR. KATZ: Oh, thank you, Dave
- 18 Harrison.
- 19 All right. Finally, there are no
- 20 members of the public in the room.
- But on the line, any members of

- 1 the public who would like to identify
- 2 themselves?
- 3 MS. K. JOHNSON: This is Karen
- 4 Johnson, one of the petitioners.
- 5 MR. KATZ: Welcome, Karen.
- 6 MS. TRIPLET: Tina Triplet, one of
- 7 the petitioners.
- 8 MR. KATZ: And welcome, Tina.
- 9 MS. M. JOHNSON: Mary Johnson.
- 10 MR. KATZ: Mary Johnson. Thank
- 11 you.
- 12 Very good. So let me just ask for
- 13 all of you on the line, please mute your
- 14 phones except when you're addressing the
- 15 group. For those of you that don't have a
- 16 mute button on your phone, if you hit *6,
- 17 that'll mute your phone. And then if you hit
- 18 *6 again, it'll unmute your phone. So *6.
- 19 And please, do not put the call on
- 20 hold at any point, but hang up and dial back
- in because the hold will disrupt the call for

- 1 everyone else.
- Much thanks. And Mike, it's your
- 3 agenda.
- 4 CHAIRMAN GIBSON: Okay. Hope
- 5 everyone's got a copy of the agenda. Sorry I
- 6 was late getting it out. But it's pretty
- 7 straightforward, I think.
- We have a few documents to go over
- 9 but I thought, to start off, maybe we could
- 10 have someone from DCAS just give us a brief
- 11 overview of the Weldon Springs ER report and
- the original SEC petition, just to get us back
- 13 up to date.
- 14 MR. ROLFES: Sure can. And I just
- 15 had it pulled it up, and I need to pull it
- 16 back up here. I just accidentally closed it.
- 17 If you could just give me a couple of
- 18 seconds.
- 19 Okay. Sorry about that.
- 20 Okay. This is just a brief update
- on SEC-00143. We received the petition in

It qualified September 11, 1 April of 2009. 2 2009 and the price evaluated by NIOSH was all 3 employees of the Department of of 4 Department Energy contractors or 5 subcontractors who worked in any area of the 6 Weldon Spring Plant or Weldon Spring 7 during the covered operational period from 8 January 1, 1957 through December 31, 1967. 9 The Evaluation Report was approved 10 in April of 2010 and the feasibility determination was that the documentation and 11 12 records that we have allow us to do accurate dose reconstructions -- dose reconstructions 13 of sufficient accuracy for both internal and 14 external sources of radiation exposure. 15 16 Would you like any additional details? 17 18 CHAIRMAN GIBSON: there Are any 19 other questions about the petition or at least what we're starting from here today? 20 21 (No response.)

- 1 CHAIRMAN GIBSON: If not, we can 2 get right into the -- SC&A has prepared an 3 matrix for the Weldon Spring issues Evaluation Report and the SEC petition. 4 we're able to take off with that, we'll go 5 6 there. 7 MR. FITZGERALD: Yes. Let me just preface -- Ron's going to go through that. 8 9 We sent that matrix out yesterday 10 afternoon. And again, it was in DOE clearance for a bit. 11 So hopefully everyone 12 has a copy of that now. We use that as a sort of set of talking points. 13 This is Dr. Lemen. 14 MEMBER LEMEN: didn't get a copy, 15 if you sent it out 16 yesterday afternoon. 17 MR. FITZGERALD: It's on the CDC But you don't see it? 18 computer.
- MEMBER LEMEN: Well, I have trouble with the CDC computer. I'm not

21 cleared for it for some reason. I'm trying to

- get cleared for it. But maybe if you sent it
- 2 to my regular email.
- MR. KATZ: I think we're going to
- 4 try to figure out how to forward that to you.
- 5 MEMBER LEMEN: Okay. Thank you.
- 6 MR. FITZGERALD: I quess with
- 7 that, as we do on these initial work group
- 8 meetings, we're going to walk through what we
- 9 see are some of the issues that either are, in
- 10 our mind, a technical question or areas where
- 11 I think we need clarification on the
- 12 evaluation. I mean, these are all created
- 13 equal. But we want to make sure at least
- there's a complete listing at this point in
- 15 time.
- 16 MR. KATZ: Dick, Mike's emailed it
- 17 to you, so it should arrive soon.
- 18 MEMBER LEMEN: Okay. I should get
- 19 it in a few minutes if he did because I can
- 20 get it from Mike.
- 21 MR. KATZ: Thanks.

- 1 MR. FITZGERALD: It's ten pages,
- 2 Dave.
- MEMBER LEMEN: Okay. Thank you.
- 4 MR. FITZGERALD: So we're just
- 5 going to go ahead and walk through this. And
- 6 Ron's done the yeoman's job so I'm certainly
- 7 going to turn to him to go through the issues
- we have.
- 9 You want to just tick through?
- DR. BUCHANAN: Okay. Before we
- 11 get started on the individual issues, just to
- 12 bring everybody up to speed, I think we ought
- 13 to cover a little bit about what the whole
- 14 facility was about and why we have an SEC.
- 15 Okay. Weldon Spring was the
- 16 uranium processing plant, and it operated from
- 17 1957 to 1966. It took over the job of the
- 18 Mallinckrodt downtown uranium plant in
- 19 downtown St. Louis. There was a slight
- 20 overlap -- a year and a half or so -- that
- 21 they both operated. The Mallinckrodt -- a lot

of you are familiar with that downtown plant.

I know Arjun is and he worked some on that.

3 And then the Weldon Spring took it of directed, 4 over, and was more 5 engineered plant to process uranium ore 6 concentrate. It essentially took the uranium ore concentrate, did chemical processing on 7 it, put it into a furnace, melted it down into 8 9 uranium metal mostly and shipped it out to other areas -- other labs and stuff to be made 10 into reactor fuel elements. 11 There were some 12 other products, but that was the main product.

As far as SC&A can find and then NIOSH has found, it used mainly uranium ore concentrate. It did not use pitchblende or the other material that came in with a lot of the byproducts of the decay in it. And so it received these in drums in something like a 55-gallon drum. They dumped uranium ore.

After the chemical processing at

NEAL R. GROSS

the mills, it came in looking something like a

13

14

15

16

17

18

19

20

21

- 1 yellow cake, so that they called it yellow
- 2 cake. They sampled these, weighed them, put
- 3 them in a hopper. And then that material went
- 4 down through a chemical separation process.
- 5 And then I don't know all the details as far
- 6 as the chemistry goes, but they created a
- 7 green salt and then they put that into a
- 8 furnace -- in a bomb, they called it. They
- 9 had to use magnesium to heat it up. And out
- of the bottom of the container then came the
- 11 molten uranium which they called an ingot.
- 12 And then that was screwed into rods, and then
- 13 rods in the machine and cut into certain
- 14 lengths. And those were then shipped out.
- 15 That was their end product. That was in `57
- 16 through December of `66.
- 17 They also used some thorium -- did
- 18 some thorium processing from `63 to `66 in
- 19 certain buildings at Weldon Springs.
- December 31st in 1966 was the
- 21 official cut-off date, I guess. They decided

- that it was no longer economically feasible to run Weldon Springs. And so they closed it
- down. It started a decrease in productivity
- 4 and worker count in the 1966 year. And then
- 5 the 1st of January of '67, it appears that
- 6 there was no real work being done there.
- 7 Now in '67 and '68, it was an Army
- 8 site to begin with. It was turned over to DOE
- 9 for the uranium processing. It was turned
- 10 back over to the Army for manufacturing Agent
- 11 Orange herbicide. It never was done.
- 12 However, there was some work done in '67 on
- some of the buildings and '68 to renovate it
- 14 for the production of a herbicide. And that
- 15 will be one of the issues we talk about a
- 16 little later.
- 17 And so I wanted to give you a
- 18 background on what it's function was.
- 19 According to records and according to NIOSH,
- 20 they received mostly uranium from the United
- 21 States and Canada, received recycled uranium

- 1 starting in -- and this is another issue, what
- 2 date is not sure -- it's around '61 -- and
- 3 Fernald mainly as some of their work. It also
- 4 received enriched uranium in a one- to two-
- 5 percent range from Fernald also in the later
- 6 years.
- 7 And so, what SC&A did, we did
- 8 worker interviews about a couple years ago.
- 9 We also evaluated the Technical Basis
- 10 Documents 1 through 6 that were issued in
- 11 2005. We evaluated those and sent that report
- in in February of '09 with 28 issues as far as
- 13 TBD issues go. And as Mark says, the ER then
- 14 was issued in April of 2010 -- somewhere
- 15 around that. And so we were charged with
- looking at the ER and evaluating it to see if
- it was technically correct.
- 18 And so we did that. And I created
- 19 the matrix with nine issues to be resolved on
- 20 it. I do apologize for getting it in late. I
- 21 know I hate it when I receive something at the

SC&A did send this in around the 1 last minute. 1st of October. 2 It took quite a while to 3 clear so it didn't and get out to computers until yesterday, apparently. And so 4 we made extra copies for anybody that needs it 5 6 here. However, I realize that this doesn't 7 give you a chance to look it over beforehand. 8 So we'll try to go through each 9 issue and explain why we bring these issues up 10 today since some of you hadn't had a chance to study it. 11 12 And we have nine issues that we'd like to bring forth to the Working Group for 13 them to consider that need resolving and what 14 can be done to resolve these issues. 15 And are there 16 we'll just start off with, 17 questions at this point on the function of Weldon Spring or where we are at this point? 18 19 MR. ROLFES: Ron, just before we 20 start, Ι want to make sure that our contractor's on the phone so they can follow 21

- 1 along.
- 2 MEMBER LEMEN: This is Dick Lemen.
- 3 I do have it now.
- 4 MR. ROLFES: Okay. Mel, Bob and
- 5 Monica, do you have copies of the document?
- 6 We're going to discuss the site Special
- 7 Exposure Cohort evaluation matrix that we
- 8 received yesterday. So I just want to make
- 9 sure that you have that before we start.
- 10 DR. CHEW: This is Mel. I do.
- 11 MR. ROLFES: Okay. I realize we
- haven't had time to prepare responses. So
- this is sort of going to be on the fly. So
- 14 we'll certainly hear what you have to say.
- 15 And just keep in mind that we haven't prepared
- 16 responses to these and that we're going to
- 17 need to do some additional research to
- 18 formulate our official responses.
- 19 MR. HINNEFELD: Yes, I think our
- 20 conversation today is more for questioning to
- 21 make sure we understand the nature of the

- 1 finding and what would be expected for the
- 2 finding to not be a finding -- those kinds of
- 3 things -- if we have any questions.
- 4 MR. KATZ: Ron, maybe as you go
- 5 through these, if some of these issues are
- 6 overlapping with issues that were raised in
- 7 the TBD review, that might be helpful to know,
- 8 since the TBD review was done back in
- 9 February.
- 10 DR. MAURO: Ron, this is John
- 11 Mauro.
- 12 And Stu, just a quick question.
- 13 I'm looking at the matrix and I see that in
- the far right-hand column -- the fourth column
- 15 -- gives the SC&A summary of the issue. But
- 16 the middle one has a NIOSH ER position. Is
- 17 this write-up something that NIOSH prepared or
- is it something that we prepared based on our
- 19 understanding of the NIOSH ER?
- DR. BUCHANAN: John, this is Ron.
- 21 Yes. The latter is correct. This

- is SC&A's reading of NIOSH's position the way
- 2 we understand the ER.
- DR. MAURO: Okay. So we don't
- 4 have before us, then, NIOSH's own response to
- 5 our concerns?
- DR. BUCHANAN: No, because they
- 7 haven't seen our concerns yet.
- 8 DR. MAURO: Very good. Thank you.
- 9 DR. MAKHIJANI: Well, we have with
- 10 the ER. We have NIOSH's Evaluation Report.
- DR. BUCHANAN: Right. And in the
- 12 third column, this is the way we understand
- what they're saying.
- DR. MAURO: Okay.
- DR. BUCHANAN: In my
- interpretation. So if it's incorrect -- as we
- go through this, if there's anything that you
- 18 wanted to clarify or correct, please free to
- 19 interrupt me.
- 20 MR. FITZGERALD: This has been
- 21 standard practice because clearly when we

- 1 present the matrix for the first time, one
- issue is making sure we're reading it right.
- DR. BUCHANAN: Sure.
- 4 MR. FITZGERALD: And the second
- 5 question is the actual technical issue itself.
- 6 So -- yes.
- 7 DR. BUCHANAN: And some of these
- 8 issues are perhaps SC&A's questioning the TBD
- 9 and the ER to see if they match each other.
- 10 If something has changed between the two, then
- 11 we want to know which way will be used in
- 12 actual dose reconstruction. And so that's one
- reason for us putting down what we understand
- 14 NIOSH to be saying and so we can clarify which
- 15 method is going to be used.
- So if there's no other questions,
- 17 we can get right into the heart of the matter,
- and that's on page two of the matrix -- issue
- 19 number one -- is accuracy of records not
- 20 sufficiently verified. And A and C are
- 21 together -- internal and external. A was

- 1 expounded on a little bit more in the ER than
- 2 C. But we had the same questions on both.
- First of all, can NIOSH tell me --
- 4 the CER -- how is it used in dose
- 5 reconstruction and why was it compared to the
- 6 CER? Why was Weldon Spring's hard copy data
- 7 compared to CER?
- 8 MR. ROLFES: Well, I'm going to
- 9 defer to Monica on this one because I believe
- she was the one who had gone and looked at the
- 11 CER records.
- 12 Monica, did you hear Ron's
- 13 question regarding the comparison of the CER
- 14 data?
- DR. CHEW: Mark, this is Mel.
- 16 Monica had to step out to take another call
- 17 here from another petitioner. I just got an
- 18 email from her. Maybe you want to defer it
- 19 until she gets back.
- 20 MR. ROLFES: Okay. We'll
- 21 certainly do that if we can if that's okay

- 1 with you, Ron?
- 2 MS. HARRISON-MAPLES: Mark?
- 3 MR. ROLFES: Yes?
- 4 MS. HARRISON-MAPLES: Yes. I
- 5 haven't left yet. I'm getting ready to leave.
- 6 I have about six minutes that I can address
- 7 this question real quickly.
- 8 MR. ROLFES: Great.
- 9 MS. HARRISON-MAPLES: Sorry about
- 10 that. I couldn't get off of mute.
- 11 The CER database is an electronic
- 12 record of the data that ORAU collected early
- on for epidemiology studies having to do with
- 14 Weldon Spring -- the studies having to do with
- 15 Weldon Spring. The purpose of comparing the
- two sets of data had to do with verifying that
- 17 the electronic records and the -- verifying
- 18 the pedigree of the records, basically. We
- 19 from an SEC perspective were not looking at it
- in terms of how the data was going to be used
- 21 for dose reconstruction directly because the

1 SEC doesn't really look into process 2 individual dose reconstructions that way. we do need to verify that the data that the 3 project has available to it -- both hard copy 4 5 and electronic -- we were comparing them for 6 consistency to make sure that what we had was 7 accurate and met our pedigree requirements. As far as for dose reconstruction, 8 9 the dose reconstructors, to the best of my 10 knowledge, have in their procedures that they will always go back to the hard copy record if 11 12 there is hard copy information available. So the comparison -- you're looking at it from 13 two different perspectives when you talk about 14 is it for 15 how going to be used dose This comparison will not be 16 reconstruction. used for dose reconstruction. 17 Does that answer the question? 18 Well, Monica, this 19 DR. BUCHANAN: is Ron. 20

NEAL R. GROSS

Will the CER database be used for

21

- dose reconstruction?
- 2 MS. HARRISON-MAPLES: The CER
- 3 database will only be used for dose
- 4 reconstruction in the event of an individual
- 5 dose reconstruction where there is not a copy
- of a hard copy record.
- 7 DR. BUCHANAN: How did the CER get
- 8 -- just for clarification -- how does the CER
- 9 get data if there wasn't hard copy to put it
- in originally?
- 11 MS. HARRISON-MAPLES: There would
- have been a hard copy record originally. ORAU
- 13 received the information directly from Weldon
- 14 Spring back when they were doing this
- 15 epidemiology study, and they digitized the
- 16 records. They made the database directly from
- 17 the records.
- 18 Now, if at some point in time that
- 19 record was destroyed somehow, CER would still
- 20 have that electronic database. That is
- 21 probably not going to happen. We don't see

- 1 that very often. What is more likely to
- 2 happen is that the CER database would be used
- in the event where there is no record for
- 4 someone, and they would look at it from a co-
- 5 worker kind of perspective.
- DR. BUCHANAN: Now the CER
- 7 database is not complete. It doesn't contain
- 8 all the records from Weldon Spring? Is that
- 9 correct?
- 10 MS. HARRISON-MAPLES: It contains
- 11 all the records that CER was able to get for
- 12 Weldon Spring.
- DR. BUCHANAN: Okay. But the way
- 14 I understand the comparison in the ER, some
- 15 years it might have contained 30 percent, some
- 16 60 percent, sometimes 90 percent when you made
- 17 a comparison. So the CER generally cannot be
- 18 used for dose reconstruction because it's not
- 19 complete. Is that correct?
- 20 MS. HARRISON-MAPLES: I'm not
- 21 really sure I'm understanding your question.

- 1 You're talking about for an individual dose
- DR. BUCHANAN: Yes.

reconstruction?

2

- 4 MS. HARRISON-MAPLES: If a person's
- 5 record -- an individual's record are in the
- 6 CER database, then yes, it could be used for
- 7 dose reconstruction. If an individual's
- 8 records are not in the database, then they
- 9 might be able to look at similar workers,
- 10 similar job titles and do a co-worker study
- 11 based on the CER records.
- 12 I'm not an expert in the co-worker
- 13 studies. I don't know if there might not be a
- 14 period where a partial reconstruction might or
- 15 might not be able to be done. But that's
- 16 generally how the CER database will be used.
- 17 For the most part, for individual
- 18 dose reconstructions, though, they will look
- 19 at the records of the individual.
- DR. BUCHANAN: Okay. Now for
- 21 Weldon Springs, when they have a claim and a

- dose reconstructor request data, where does
- 2 that data come from to that --
- 3 MS. HARRISON-MAPLES: I'm sorry.
- 4 I didn't quite understand the question.
- DR. BUCHANAN: When a claim is
- 6 submitted and NIOSH processes that claim and
- 7 does a dose reconstruction for Weldon Spring,
- 8 where do they get that data that they use to
- 9 actually do the dose reconstruction? Do they
- 10 get hard copies from where? Or electronic
- 11 database?
- 12 What I'm trying to establish is
- the data they use today has been verified it
- is complete and accurate from the original
- 15 data that was recorded for that worker 40
- 16 years ago.
- 17 MS. HARRISON-MAPLES: I'm not sure
- 18 that I can answer your question fully. I
- 19 don't work on the dose reconstruction side of
- 20 it. I believe I understand the procedures,
- 21 but I work SEC side.

1 I understand it, we have out 2 for the record for Weldon Spring, we have a 3 storage of records from Weldon Spring. that would be searched to find records for the 4 That would include copies of the 5 individual. 6 hard copy record for the individual, if we 7 They might look through the have them. database. And this comparison of the database 8 9 with the hard copy is basically a verification 10 that we got these records at one time in the 11 past, we're comparing them to what 12 again, and we're verifying that they are the same in order to establish a pedigree of the 13 information. 14 for 15 DR. **BUCHANAN:** Okay. So example on page 49 of the ER, it shows -- 49 16 or 50 -- it shows that for 1957, for example, 17 results captured 18 that the SRDB in CER 19 database was 61 percent. So this tells me, number one, that the CER does not contain all 20 the records, obviously, if it contains only 61 21

- 1 percent for that year. So the SRDB database
- 2 -- this is an electronic database that was
- 3 copied from the hard records? Or how did the
- 4 --
- 5 MS. HARRISON-MAPLES: No, no.
- 6 You're confusing the purpose of the SRDB
- 7 database.
- 8 Mel, can you speak to this a bit?
- 9 I have to go. I have to pick up this other
- 10 call. I apologize and I will be back on this
- 11 call as quickly as I can be. But we have a
- 12 petitioner from another petition that I set up
- a call for and I've got to go.
- MR. ROLFES: Thank you, Monica.
- MS. HARRISON-MAPLES: I'm sorry.
- 16 Thank you.
- 17 MR. ROLFES: No problem. Thank
- 18 you.
- 19 Mel, did you want to answer Ron's
- 20 question regarding the Site Research Database
- or should we wait for Monica?

- DR. CHEW: I think we should table
- this thing, Mark.
- 3 MR. ROLFES: Okay.
- DR. CHEW: I'm not so sure I
- 5 understand exactly where Ron is going with
- 6 this question, anyway.
- 7 MR. HINNEFELD: This is Stu.
- 8 Well, one question that comes to
- 9 mind is what is the origin of the exposure
- 10 record we receive when we get an exposure
- 11 history from a Weldon Spring worker. Weldon
- 12 Spring is not there anymore. Does this go to
- 13 Legacy Management, and what record do they
- 14 pull out? What do they rely on to tell us
- 15 what the exposure record is? I mean, that's
- 16 one question.
- 17 DR. BUCHANAN: That's correct.
- 18 And what's the chain of custody, so to speak?
- 19 When it was recorded in 1962 to when the dose
- 20 reconstructor -- I quess this is the summary
- of the issue is for external and internal

- 1 records. What is the chain of custody? What
- 2 is the verification that the dose
- 3 reconstructor receives? If it's an electronic
- 4 database, is it a photocopy or whatever, how
- 5 do we know that that is complete from when
- 6 that record was recorded in 1962 or whenever
- 7 the operation's taking place during the SEC?
- 8 That is what I would like to be addressed.
- 9 DR. CHEW: So Mark, let me make it
- 10 -- I think we need to get someone who was
- 11 doing the dose reconstruction from Weldon
- 12 Spring to answer that particular question.
- MR. ROLFES: That would be a good
- idea. I don't know if Dave Harrison might be
- 15 familiar with that or not.
- Dave, did you have anything to add
- 17 about the source of the DOE records that we
- 18 received for dose reconstructions for Weldon
- 19 Spring Plant?
- 20 MR. HARRISON: I do not have that
- 21 information right now.

1 MR. ROLFES: Okay. Thank you. 2 We'll have to get you an answer 3 for that. I was trying to look on my computer but it's not very responsive 4 the 5 moment. 6 FITZGERALD: the MR. Yes, two 7 facets -- and this is sort of a conventional question we raise with every SEC as sort of 8 9 the source of the database that's being used 10 for dose reconstruction. And the other thing 11 that I think that Ron was getting to is how 12 you validated that the database track sufficiently complete. if 13 And there gaps, how did you address the gaps? 14 that's kind of where we always come from. 15 16 DR. MAKHIJANI: Just to add 17 something to that, part of our procedure is to And the Board's guidelines for 18 review these. 19 us were to look at adequacy and completeness. 20 you're going to do co-worker models, they'll probably come from this electronic 21

- database. And then we're supposed to verify
- 2 the adequacy of that electronic database. So
- 3 if 40 percent of the records are missing in
- 4 some cases, then you want to know which 40
- 5 percent are missing.
- 6 MR. FITZGERALD: Right. And how
- 7 representative would it be if you did --
- 8 DR. MAKHIJANI: Yes,
- 9 representativeness, adequacy and completeness
- 10 are part of our kind of SEC review guidelines
- 11 that we need to ask those questions.
- 12 DR. BUCHANAN: A lot of these
- 13 records have been transformed to electronic
- 14 records through the years. And then that gets
- 15 put into another system. And so we have some
- sort of verification from the very origination
- 17 of those records to the use of dose
- 18 reconstruction to make sure that they're there
- and they've been transferred accurately.
- 20 So that's issue 1 -- A and C on
- 21 the records. And the reason I put those in

- there is because the way I understand it is
- that on B, we might as well pop into that now,
- 3 it's air data.
- 4 I understand that according to the
- 5 ER and TBD that there is uranium air
- 6 monitoring data area and some breathing zone
- 7 area for 1958 through 1966. That's on page 40
- 8 of the ER. And for thorium, 1963 to 1966 on
- 9 page 41 through 45. And am I to understand --
- 10 recommend using TIB-5000 and 6000 for using
- 11 this data which consists of daily weighted
- 12 averages -- DWAs -- which I understand they
- 13 would put an air sample there for a certain
- amount of time, determine how long that exists
- 15 and then prorate that for like an eight- to
- ten-hour shift or something?
- 17 However, I'd like Arjun to address
- 18 that since he's addressed this at
- 19 Mallinckrodt, perhaps, Fernald. So he has
- some insight and experience in this area.
- DR. MAKHIJANI: Yes. I've only

- 1 been marginally involved with Weldon Spring
- 2 just kind of answering Ron's questions off and
- 3 on.
- 4 And one of the questions was what
- 5 have we said and what methods have we
- 6 recommended in using daily weighted average
- 7 data. And there was a whole analysis in our
- 8 report to the Board in April 2005 when we
- 9 showed that the use of daily weighted averages
- 10 could give you or indicate at least by an
- analysis that could give you average typical
- 12 doses for a group of workers. But it
- 13 certainly couldn't establish bounding values.
- 14 Very often you have two or three measurements
- 15 at a job location.
- 16 PARTICIPANT: Your broadcast is
- 17 breaking up here. Could you get closer to the
- 18 microphone, please?
- 19 DR. MAKHIJANI: Yes. Well, in
- 20 April 2005, we had -- I'll speak a little
- louder too. In April 2005, we had done an

1 analysis of the daily weighted average 2 question in the context of the Mallinckrodt 3 SEC review and pointed out that you can't use 4 daily weighted averages to with come up bounding doses for anything -- maybe typical 5 6 doses for a group of workers. And there were 7 a number of reasons for that. And we also 8 recommended approach that an you might 9 consider for use of daily weighted averages to 10 develop such bounding doses. But Ι don't believe it's ever been done. 11 12 And it by we ran our And the basic issue -- just to 13 statisticians. remind you -- and I'd be happy to send that 14 report to all of you who may not currently 15 16 have it; I don't think it's on the NIOSH 17 website -is that you have two or three 18 measurements taken over a few minutes for each 19 task that was performed over the course of a 20 day. Very often these two three or

NEAL R. GROSS

а

certain

task

for

measurements

21

would

1 highly variable. In some cases, many 2 measurements were taken but only the minimum, 3 maximum and averages reported so there's a significant loss of data so you can't actually 4 construct the distribution, or at least what 5 6 is presented in the database doesn't contain 7 all the information that was originally taken. 8 And when you try to calculate the 9 variances based three, four on two, 10 measurements, they are of course very large. And then there are different variances for 11 12 each task. So there are a number of tasks that go into a daily weighted average, and 13 you're confronted with a problem of coming up 14 composite distribution that 15 with would representing a bounding dose. 16 It's a non-trivial problem. 17 And it's unclear, with a few measurements over a 18 few minutes which was typical. 19 I haven't looked at Weldon Spring data -- which was the 20 case at the Destrehan Street site -- that you 21

- could do this. I mean, we didn't offer an opinion so far as I remember. We suggested
- 3 that if it were going to be used to develop
- 4 bounding doses that there was a possible
- 5 approach that could be developed. But we
- 6 never saw any response from NIOSH, presumably
- 7 because an SEC was granted at Mallinckrodt and
- 8 NIOSH didn't have to go there.
- 9 But subsequently, I've noted that
- 10 NIOSH has proposed the use of daily weighted
- 11 average in the same way and sometimes in
- 12 moderate variance but never addressed our
- original criticisms of use of daily weighted
- 14 averages in the SEC context.
- 15 MR. HINNEFELD: What was your
- 16 report that you -- or what was it related to
- 17 at --
- 18 DR. MAKHIJANI: It was the
- 19 Destrehan Street site from April 2005.
- 20 My government computer has kind of
- 21 locked up. It's not working right. And I

- 1 have to call -- my whole email has crashed.
- 2 But I think I can send things out.
- MR. HINNEFELD: I can find what
- 4 you described. I'll be able to find that.
- 5 MR. MORRIS: Yes, in 2005, that
- 6 would not have had a DOE classification
- 7 review. So you're probably not authorized to
- 8 handle it over the Internet yet.
- 9 MEMBER LEMEN: Hello. This is Dr.
- 10 Lemen. Can you hear me?
- 11 MR. HINNEFELD: Yes, we can hear
- 12 you, Dick.
- 13 MEMBER LEMEN: Arjun, would it be
- 14 possible for you to send me that report if you
- 15 can find it?
- DR. MAKHIJANI: Sure. I can send
- 17 it. I have it in my government computer
- 18 because I have all my files.
- 19 MR. MORRIS: But are you aware
- 20 that DOE has probably not reviewed a 2005
- 21 document?

- DR. MAKHIJANI: This raises a
- 2 point. We are not allowed to send any files
- 3 prior to 2008 to anybody?
- 4 MR. FITZGERALD: It's probably
- 5 appropriate to send it through DOE for a check
- 6 before doing it yourself. I mean, just
- 7 retroactively because we had that issue going
- 8 back before 2006.
- 9 DR. MAKHIJANI: But presumably
- 10 internal SC&A, we can still see it. Because
- 11 it's on my --
- 12 MR. FITZGERALD: Yes, just for
- 13 dissemination. I think there's an
- 14 acknowledgment that there's some documents
- 15 that go far back that --
- DR. MAKHIJANI: Right. Sure.
- 17 MR. FITZGERALD: -- there's a
- 18 limbo status. But we still want to go ahead -
- 19 -
- DR. MAKHIJANI: Well, I'm happy to
- 21 go along with whatever direction CDC has to

- 1 provide. Ted?
- MR. KATZ: Yes, that makes sense
- 3 to me.
- DR. MAKHIJANI: So reports that go
- 5 to the Board and to NIOSH should be run by DOE
- 6 before sending --
- 7 MR. FITZGERALD: If they haven't
- 8 been screened. That's the protocol. Yes.
- 9 DR. MAKHIJANI: Okay.
- DR. MAURO: This is John. Try
- 11 speaking as if you just did very briefly on
- 12 breathing zone data and daily weighted
- 13 averages. This has been a subject that's come
- 14 up as Arjun pointed out on a number of
- 15 occasions. It also will be an important issue
- on our upcoming Fernald meeting.
- 17 And I just wanted to say
- 18 something, I guess, more global. The health
- 19 and safety laboratory which made wide use of
- 20 this technique and is widely accepted in the
- 21 industrial hygiene world as an excellent way

to get a good sense of the kinds of exposures different jobs, different workers and job

categories experience.

The way it's implemented, when you actually go through the calculations, you look at the data, it's instructive to actually do I've done a couple myself just to make one. sure I understood how they're done. What you really come up with is a best estimate of the exposure of a worker in a given day for his given job category. And I think that's an excellent metric to characterize the kinds of inhalation exposures exposures different classes of workers might achieved.

But now, it's widely accepted within NIOSH that this is reasonable а and it's been approach to take embraced. We're really questioning whether or not the intent of the DWE approach that has been embraced really meets the intent of EEOICPA,

NEAL R. GROSS

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

which is different than what HASL was trying

2 to do when it invented or applied, or 3 industrial hygiene community, in general. think that the number you end up with by way 4 5 of intake represents reasonable а best 6 estimate for a given category of work or a job 7 But there can be many workers that category. 8 fall within that category that could 9 experience exposures that are substantively 10 higher and perhaps substantively lower since it's a parameter that tries to capture central 11 12 tendency. So as applied to this program, the 13 classic approach doing daily weighted 14 to exposures may not really meet the intent --15 and the reason I'm bringing this up is this 16 becomes a global issue in terms of, does NIOSH 17 18 agree that yes, SEC, I think you're right. Ι think that it gives a good best estimate. 19

NEAL R. GROSS

is that really what we're looking for? Aren't

something that

we

looking

for

20

21

1

provides

- reasonable bounding estimate so that no worker's exposure is underestimated?
- 3 And I think once that distinction
- 4 is recognized and acknowledged and is
- 5 explored, NIOSH may decide no, no, SEC, we
- disagree, this is fine. Or no, you're right.
- 7 And I think this is something that is so
- 8 fundamental to the dose reconstructions we've
- 9 been doing where we rely on breathing zone.
- 10 As Arjun pointed out, if it's
- 11 decided by NIOSH that maybe perhaps we should
- 12 revisit this concept, we do offer up -- and
- that's why it's very important that Arjun's
- 14 write-up on Mallinckrodt is distributed
- 15 because he actually lays out a statistical
- 16 approach using the data that will tend to
- 17 generate an approach of what I would say is
- 18 more claimant-favorable than the classic
- 19 breathing zone.
- 20 So I wanted to make this point
- 21 because it might actually be something that

- goes toward one of these global issues because
- 2 it cuts across many sites.
- 3 MR. MORRIS: This is Bob Morris.
- 4 In response to that, John, I'd ask you a
- 5 question. Have you guys seen the 9 February
- 6 2008 peer-reviewed Health Physics Journal
- 7 report by Adams and Strom regarding DWE
- 8 uncertainty and how DWE data may be
- 9 specifically used in dose reconstructions
- 10 under this program?
- 11 DR. MAURO: I haven't read it.
- 12 I've seen it but I have not read it.
- So I guess you're saying that the
- issue may be very well aired in that article.
- 15 MR. MORRIS: It is a very well
- 16 done article.
- DR. MAURO: I think it's important
- 18 that we all take a look at that as part of
- 19 this process.
- DR. MAKHIJANI: But you haven't
- 21 proposed --

- 1 MR. MORRIS: The 2008 Health
- 2 Physics Journal.
- MR. HINNEFELD: Bob, this is Stu.
- 4 Which journal is that in?
- 5 MR. MORRIS: February 2008 Health
- 6 Physics Journal --
- 7 MR. HINNEFELD: Okay.
- 8 MR. MORRIS: -- by Adams and
- 9 Strom.
- DR. MAKHIJANI: But you haven't
- 11 proposed to use that here.
- 12 MR. MORRIS: We've used it as
- underlying a lot of our approach to DWE data.
- 14 It's inherent in our approach. If you read
- 15 how we're actually using it in our revised
- 16 Technical Basis Document drafts and such,
- 17 you'll see that that's one of our underpinning
- 18 documents that's referenced.
- DR. MAKHIJANI: Yes. Okay. Fine.
- DR. MAURO: That's very helpful.
- 21 I'm going to look at that right away.

1 DR. MAKHIJANI: But the only thing 2 like to add from what John said is we 3 didn't actually develop this method because 4 it's NIOSH's to do. 5 MR. MORRIS: Could you move 6 closer, please? 7 That's NIOSH's job DR. MAKHIJANI: 8 to develop the method. We critiqued the 9 application of DWE directly and suggested that 10 there could be approach to develop an But we didn't actually ever say that 11 method. 12 here's the method; this will work. Here's the kind of data that go into it. 13 In my opinion, probably it might depend on a case-by-case 14 15 If you've got too many tasks with two basis. data points, you might have problems. 16 have more data points for each task 17 18 reliable task profile, that might work. 19 MR. MORRIS: What Strom and Adams 20 suggest in that context is that as those 21 uncertainties the geometric that go up

- 1 standard deviation applied to the data set
- 2 goes up.
- DR. MAKHIJANI: Yes.
- 4 MR. MORRIS: So I think there's a
- 5 logical approach that they've prepared
- 6 considering exactly those concerns.
- 7 DR. MAKHIJANI: I'm aware of the
- 8 geometric standard deviation issue, and we
- 9 pointed out the same thing in 2005. But all I
- 10 wanted to say in this context, just to
- 11 clarify, is that we indicated a path that was
- 12 a possible path but never signed off because
- 13 NIOSH didn't develop it because it was an SEC
- 14 --
- 15 MR. FITZGERALD: Right. And we
- 16 can certainly review it. I'd be happy to do
- 17 that.
- 18 DR. MAURO: Yes, Arjun, thank you
- 19 for clarifying that. I know I didn't mean to
- say that we're offering it up. But there are
- 21 strategies that could be used.

Bob, one real quick question for you because you really got my attention. This might be the magic bullet.

When I've reviewed and done some of these, there would be a person that had a particular job category at a facility. And on a given day, he would spend let's say one hour shoveling dirt. I'm making this up. And where I know this -- okay -- this would be the smallest element that makes this uр DWE calculation.

So here you have this guy. In a given day we know he spends about an hour or two doing a particular task -- very specific task. And what I would always notice is that they were usually reported for him a breathing zone sample -- three of them. They were to report three of them. Not that they had only three, but they would report three. They would say here's the lowest one we saw, here's the middle one, and here's the highest in

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

terms of the becquerels per cubic meter that he was exposed to during the time that the air sample was collected -- the low, medium, high.

What would happen is they would take the average of those three numbers, and that would represent his exposure for that one-hour time period when he does that job -- that's my understanding for better or worse of the essence of the DWE exposure. And then they process the numbers over and over.

But if you take the average, what you've just done was take what you would consider to be а good central estimate for that particular one-hour job that this guy was doing. And therein lies the essence of our concern because if you have a number of people doing that job, some of them are not going to be in the center. Some of them are going to be toward the high end. those are the ones that you would not be giving the benefit of the doubt. So it was

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

- our understanding that that's the way in which
- 2 it's done.
- 3 Are you saying that the Strom
- 4 article somehow comes to grips with that in a
- 5 way that --
- 6 MR. MORRIS: Excuse me. I'm
- 7 sorry. I didn't mean to interrupt you, John.
- DR. MAURO: Yes.
- 9 MR. MORRIS: It's been a half a
- 10 year or more since I've read it. So be
- indulgent on my memory here.
- 12 But I'm recalling that he included
- 13 a method or way to assume log-normality in
- 14 that data set representative of only like
- three low, medium and high where it might be
- more data that were actually collected and not
- 17 reported in the summary level.
- 18 DR. MAURO: Absolutely. We're on
- 19 the same page now because that's how we were
- 20 looking at it also. Keep going.
- 21 MR. MORRIS: And so I think that

- 1 the method incorporates some function like
- that and in fact addresses it. So that's
- 3 really all I'm prepared to say because I
- 4 didn't anticipate this conversation today.
- DR. MAURO: This is great. It's
- 6 important. I'm going to take a look at it. I
- 7 think the other members of our crew -- because
- 8 when I do do it by hand -- and I've done these
- 9 by hand to match your numbers -- it was always
- 10 the average. But if somehow -- maybe I looked
- 11 at an example. There was a recent one. I
- 12 forget which one it was. I said, this is the
- 13 essence of our concern.
- 14 But if in other venues, you're
- using let's say the Strom approach which does
- somehow factor in that there is a distribution
- 17 and tries to grab something closer to the
- 18 higher end as a way of propagating the number,
- 19 well, I think that would go a long way to
- 20 resolving our concerns. But we have to look
- 21 at this.

1 MR. MORRIS: Okay. Now the one 2 thing I'd say is that they actually 3 developed their method and tested it with AWEtype data, and it represents four or five 4 5 different sites and shows that it's possible 6 to come up with bounding estimates with this 7 method. So I don't want to over-represent 8 9 it, but it's an extensive article that's 10 directly pertinent to the kind of data that we 11 see. 12 DR. MAURO: Very good. Thank you. 13 MR. MORRIS: Sure. MR. FITZGERALD: And just to close 14 that discussion, you said that's wired 15 into NIOSH's procedures by virtue of the OTIB? 16 Or was that just sort of part of the standard 17 I just wanted to understand how 18 practice now? that's being implemented. 19 20 don't MR. MORRIS: We have procedure that's titled daily weighted average 21

- or daily weighted exposure. But when we
- 2 develop the Technical Basis Document to come
- 3 up with intake rates, you'll see that that is
- 4 a referenced document in the technical basis.
- 5 MR. FITZGERALD: Okay. So it's
- 6 referenced in --
- 7 MR. MORRIS: Yes. And it
- 8 certainly underpins what we've done. And you
- 9 can see that it really is one of our central
- 10 references on this topic.
- DR. MAKHIJANI: I don't think it's
- 12 referenced in the Weldon Spring Evaluation
- 13 Report.
- 14 MR. ROLFES: Well, right now what
- 15 we have in the Weldon Spring Site Profile is
- 16 thorium intakes using surrogate data from
- 17 Fernald. And as a result of the SEC petition
- 18 evaluation, we indicated that we would use
- 19 site-specific data for the Weldon Spring
- 20 Plant. And so as part of the revision right
- 21 now that's ongoing with the Weldon Spring Site

- Profile, we are looking at the individual air monitoring results and data that we have for Weldon Spring Plant operations and using that
- 4 in our revision for Weldon Spring.
- 5 certainly looking So are we 6 this issue, it's something that we're and 7 We're going to take what you've aware of. 8 written down into consideration as a part of 9 that revision as well.
- One other thing to remember about daily weighted averages is typically those operations didn't last the entire year. And many of the higher air concentrations had documentation indicating that the workers were required to wear respiratory protection.
- 16 When we would take t.hat. air 17 monitoring data, we had to use it for dose reconstruction. would not reduce 18 We the intake values due to respiratory protection. 19
- 20 Also, we would apply a full year 21 of intake based on that air concentration -- a

- 1 full 2,000 hours per year -- certainly
- 2 acknowledging that that operation may not have
- 3 occurred that entire year or may have just
- 4 been a short production run or a couple of
- 5 months.
- 6 So anyway, those are things that
- 7 we will certainly update in the Site Profile
- 8 revision.
- DR. MAKHIJANI: Well, Mark, as
- 10 you're doing that, you might consider the
- 11 literature that indicates it's pretty hard to
- 12 establish a relationship that's definitive
- 13 between air concentration data and bioassay
- 14 data, when both are available.
- 15 I think there may even be some
- 16 literature from Weldon Spring along those
- 17 lines, but I'm not sure. I'll have to check
- 18 on that.
- 19 Ron, did I send you something
- 20 along those lines? We can talk off line. I
- 21 can't recall right now.

- 1 MEMBER LEMEN: This is Dr. Lemen
- 2 again.
- 3 Is this the Adam Davis and Strom
- 4 article?
- 5 MR. MORRIS: That's right. It is
- 6 in 2008, if I recall.
- 7 MEMBER LEMEN: You said they used
- 8 for Board compensation but in the article
- 9 itself it says that there were overestimates
- 10 as well as underestimates by factors -- of the
- 11 underestimates by three to ten. So do you
- 12 really think that --
- 13 MR. MORRIS: I think he should
- 14 spend some more time with the article before
- 15 we have that conversation.
- 16 MEMBER LEMEN: All right. Because
- it doesn't appear to say what you just said it
- 18 said.
- 19 MR. MORRIS: Well, as I said, it's
- 20 been half a year or more since I read it. But
- in my view the bottom line of the report goes

- 1 to a recommendation about how to use the data,
- demonstrates that it can be used and suggests
- 3 some bounding approaches that are based on
- 4 using large geometric standard deviations.
- 5 MEMBER PRESLEY: This is Bob
- 6 Presley.
- 7 How much thorium contamination are
- 8 we really talking about?
- 9 MR. ROLFES: Well, the amount of
- 10 thorium that was processed at the Weldon
- 11 Spring Plant was less than one percent of the
- 12 uranium that was there. So -- and it was only
- 13 during the later part of the operational
- 14 period from '63 through '66. So I don't
- 15 recall the exact number of months, but we
- 16 have, I believe in our Evaluation Report, we
- 17 had identified the buildings that had
- 18 processed thorium and the time periods as
- 19 well.
- 20 MEMBER PRESLEY: So it's less than
- 21 one percent?

The 1 MR. ROLFES: Correct. 2 material that was produced -- the thorium-232 3 material that was produced from 1963 through 1966 was less than one percent of the total 4 uranium or special nuclear material throughput 5 6 at the site. 7 Well, we're not MEMBER PRESLEY: talking about much contamination. 8 9 Well, the percents DR. MAKHIJANI: 10 don't matter as much as the total quantity. At least in your site -- I haven't researched 11 12 the source term independently, but in your Site Profile, if I recall correctly, it says 13 about one ton per day of thorium. And that's 14 a non-trivial amount. 15 You might recall at Y-12, we had 16 discussion in the SEC -- and you'll recall 17 Presley -- that initially it was 18 this, Mr. 19 thought that there were a few kilograms here But when Mel Chew and his group 20 and there. discovered that there hundreds 21 were of

- 1 kilograms or tons in total, the tons in total
- 2 was considered a significant amount. Here
- we're talking a ton per day. So that's a non-
- 4 trivial amount of thorium.
- 5 And it's also important to note
- 6 that one percent thorium -- if you're looking
- 7 at organ doses and dose conversion factors --
- 8 one percent of thorium in terms of mass would
- 9 be approximately equivalent in terms of bone
- 10 surface dose to -- one unit of thorium would
- 11 be approximately equivalent in bone surface
- 12 dose to 100 units of uranium. So you're
- 13 talking -- for some organs -- for other organs
- it's comparable to uranium. But for bone
- 15 surface, the dose conversion factors for
- 16 thorium are a couple orders of magnitude
- 17 bigger.
- 18 So small quantities of thorium can
- 19 convert into considerably larger doses than
- 20 uranium. That's just how the numbers work.
- 21 MR. ROLFES: Right. We certainly

- 1 acknowledge that and account for it in dose
- 2 reconstruction.
- DR. MAKHIJANI: Yes, right. I'm
- 4 not saying you don't.
- 5 I'm just saying that you can't say
- 6 it's one percent and therefore it doesn't
- 7 matter. There are two ways in which it
- 8 matters, and I've just tried to point that
- 9 out.
- DR. BUCHANAN: And another way it
- 11 matters is that if these were campaigns, and
- 12 so a worker, he wasn't exposed to 99 percent
- 13 uranium and one percent thorium during that
- period, he was exposed to 100 percent thorium
- if he was on that campaign.
- DR. MAKHIJANI: Right.
- 17 DR. BUCHANAN: And so it wasn't
- 18 diluted with 99 parts of uranium. And so he
- 19 was exposed to the thorium during those
- 20 months, days or years or whatever it was. He
- 21 was working on it in those buildings. So it

wasn't a mixture that was flowing through the whole system.

3 Yes, that certainly MR. ROLFES: would be the bounding situation for 4 an being exposed purely to thorium. 5 individual 6 So what we would do for an individual, say he 7 worked in 1963 with thorium -- and I think we provided a sample dose reconstruction to the 8 9 Advisory Board on how we would reconstruct a 10 thorium intake. But I'd have to go back and 11 check and make sure.

> We would apply air an individual, concentration to that apply intake for 2,000 hours per year, and assign that thorium-232 exposure. However, if that individual also had a uranium bioassay during would apply a uranium that year, we same intake well. And typically, when as we complete а dose reconstruction, if the individual worked there from 1957 through 1966 and had monitoring for each of those years, we

12

13

14

15

16

17

18

19

20

21

- 1 would apply a chronic intake for the entire
- time period for all years of the employment to
- 3 ensure that we are over-estimating the actual
- 4 exposure or intake that the individual
- 5 potentially received.
- 6 So basically, our first and
- 7 foremost piece of information for a dose
- 8 reconstruction would be the bioassay data that
- 9 we've had to generate an intake. And then
- 10 secondly, for an individual perhaps that was
- 11 exposed to thorium during a short-term
- 12 operation in the later years, we would take
- that air concentration data and apply that on
- 14 top of the uranium intake.
- 15 DR. MAKHIJANI: Mark, are these
- 16 sample dose reconstructions in the Advisory
- 17 Board document? I don't see that.
- 18 MR. ROLFES: Let me check. I may
- 19 not have put them out there. And I can
- certainly do that if it hasn't been done.
- 21 MR. HINNEFELD: It seems to me

- that we're spending some length agreeing with
- each other here. We've got to move on to the
- 3 next issue.
- DR. BUCHANAN: Yes, I think that
- 5 what we want to summarize is that SC&A will
- 6 need to look at the Health Physics 2008
- 7 article, and then come back to the table and
- 8 see how we evaluate that. Is that in
- 9 agreement?
- 10 Okay. Item D on Issue number 1
- 11 was coworker data. Okay.
- 12 The comment I have on that number
- one is, of course, coworker data isn't usable
- 14 unless the data's been verified. And we
- 15 talked about that in Issue items A and C. And
- 16 we have agreed upon the direction forward on
- 17 that. So coworker data, we have to verify
- 18 that before it's useful.
- 19 Additionally, I guess going from
- 20 the TBD to the ER, my issue on coworker data
- 21 is that in the ER, I gathered that NIOSH

1 recommends using the operator's data to bound 2 everybody's data so that the environmental 3 data wasn't necessary. Is that 4 assumption? Well, certainly if 5 MR. ROLFES: 6 you're using the individuals who are directly 7 working with uranium and are monitored. Those are likely the people that are going to have 8 9 the highest exposures. Those exposures would 10 certainly bound the environmental releases and any intakes from re-suspension of contaminated 11 12 soil, et cetera. So are we going to 13 DR. BUCHANAN: use if a person wasn't badged at Weldon Spring 14 and that's about 50 -- not monitored --15 16 well, some of them weren't badged; some of monitored. 17 them weren't There were more people badged than there were bioassayed. 18 19 So the person wasn't bioassayed, 20 say he wasn't bioassayed and was

NEAL R. GROSS

would

he

be

though,

badged,

21

given

an

- 1 environmental dose or an operator's dose?
- 2 MR. ROLFES: If they were issued
- 3 an external dosimeter but had no internal
- 4 monitoring data I guess is the question.
- DR. BUCHANAN: Right.
- 6 MR. ROLFES: You'd have to take a
- 7 look to see what their job function was, look
- 8 to see what areas they worked at the plant.
- 9 One of the things that we do with
- 10 everything that we receive is the telephone
- 11 interview. So we would also have to take a
- 12 look at the details that we received in a
- telephone interview if one is available to us.
- 14 If we do not know and there's a
- 15 potential that the individual could have been
- 16 exposed to elevated levels of uranium in the
- 17 air, we would certainly apply a uranium
- 18 intake. We would give the benefit of the
- 19 doubt to the claimant. So we would apply the
- 20 higher intake --
- 21 MR. MORRIS: Can I jump in on

- 1 this, Mark?
- 2 MR. ROLFES: Yes, please, Bob.
- 3 MR. MORRIS: In the October 12th
- 4 document that SC&A -- I may be speaking here
- 5 -- the response to the SC&A comments on the
- 6 Weldon Spring Site Profile that was issued
- 7 earlier this year has got a response I think
- 8 dated October 12th from the NIOSH team.
- 9 MR. ROLFES: Correct.
- 10 MR. MORRIS: And in item 1 of
- 11 that, Ron, you'll see the approach to
- 12 occupational -- environmental dose methods
- 13 that are actually being put into a TBD
- 14 revision that is in review right now.
- 15 So let me refer you to that. And
- if that doesn't answer the question because
- 17 I'm not sure I got exactly the question you
- 18 asked, if that doesn't answer it, let's try it
- 19 again though. But if you could look at that
- written response, that would be good.
- 21 DR. BUCHANAN: Yes. I looked at

- And this is what I'd like to 1 that response. 2 that in the original clarify is TBD, 3 people that -- the way I understand it -- it's an original TBD, that if the person didn't 4 5 have bioassay, then the environmental dose 6 would be applied. And this environmental dose 7 would be taken from a hopper-cleaning and a 8 combination of that and perimeter data 9 monitoring.
- 10 We developed quite a MR. MORRIS: 11 bit more perimeter monitoring data after the 12 SEC evaluation was completed and we started Technical Basis Document revision. 13 So the perimeter data is more robust than it 14 before. 15
- DR. BUCHANAN: But it's still perimeter data. It isn't site data. Is that correct?
- MR. MORRIS: You're correct on that. But what we did was we looked at the local wetting patterns, got the atmospheric

- dispersion parameters and extrapolated that to
- the inner ring of the plant building and then
- 3 established what an air concentration and
- 4 consequent intake rate would have been in the
- 5 bounding atmospheric conditions.
- 6 DR. BUCHANAN: And this is in a
- 7 revision -- the TBD 4?
- 8 MR. MORRIS: That's right. And
- 9 it's in review inside the DCAS system right
- 10 now. It's described here for you in the
- 11 response to item number 1.
- 12 DR. BUCHANAN: Now how did the
- 13 results compare to the hopper clean-out?
- 14 Because I noticed in reviewing the TBDs, the
- 15 hopper clean-out was combined with a perimeter
- 16 then -- a perimeter data then. The perimeter
- data only contributed less than one percent to
- 18 the parameter data.
- 19 MR. MORRIS: I'm not ready to
- 20 answer that. If you want to defer that, I'll
- look for that and compare it and then answer

- 1 it later today.
- 2 DR. BUCHANAN: I think that would
- 3 be a benchmark because the hopper data was
- 4 like 100 times greater than the perimeter data
- originally. And it'd be interesting to see
- 6 how the perimeter data -- new perimeter data
- 7 -- extrapolated to the center of the site
- 8 through the hopper data.
- 9 MR. MORRIS: Yes. Well, of course
- 10 hopper clean-out is a one-time event and we're
- 11 trying to get annualizing averages for these
- 12 kinds of numbers. So I would not at all be
- 13 surprised if the hopper clean-out numbers are
- 14 still higher.
- 15 MR. HINNEFELD: This is Stu
- 16 Hinnefeld and I wondered if I might make a
- 17 process suggestion here. And it's just a
- 18 suggestion; you can do what you want.
- But we seem to be spending a lot
- 20 of time providing verbal technical responses
- 21 to the written report that we have here. And

we're ultimately going to have to provide written technical responses to this report anyway. We're not going to resolve any of these findings verbally today.

But we go through these extended technical conversations with these things, and it would seem to me that if we can just have enough conversation to understand the issue and to maybe suggest like, well, we believe we some information we've put together on TBD evaluation response that our appropriate here and we can do some brief this stuff there. Because none of discussion technical is going to anything today.

And so, Ι think we're better served with our time today -again, suggestion make sure have to we an understanding of the finding so that we provide a written technical response to the written technical finding. This is а

NEAL R. GROSS

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

- 1 suggestion.
- 2 CHAIRMAN GIBSON: That's fine with
- 3 me. Everyone okay with that?
- DR. MAKHIJANI: Could I supplement
- 5 that just slightly?
- 6 MR. HINNEFELD: Sure. Absolutely.
- 7 DR. MAKHIJANI: I agree with you.
- 8 It might be useful as I did with the issue of
- 9 air concentration just to point out as NIOSH
- is preparing its response, some of the things
- 11 that we're going to be looking at -- I mean,
- 12 this is an initial --
- 13 MR. HINNEFELD: Absolutely.
- Absolutely -- as much as we can learn, yes.
- 15 DR. MAKHIJANI: So I'd like to do
- 16 that in this case.
- 17 A couple of points that would be
- 18 useful for you to consider in your response
- 19 looking at your October 12 document here is
- one we've said before in other contexts. I
- 21 certainly recall we said it in the context of

1 Savannah River Site. And this is from memory, 2 that Gaussian dispersion plume modeling is not 3 a very good idea for on-site environmental dose calculations. You have building wake 4 effects and so you're taking perimeter models 5 6 -- perimeter measurements -- which are really 7 designed for offsite dose estimation and compliance for offsite people for which this 8 9 is a reasonably defensible approach in many 10 And then applying it cases anyway. to a situation where in many cases unless you have 11 12 broad open field on site where you're 13 placing your worker, it's not applicable technically. 14 Secondly, dispersion 15 because 16 factors can vary by two orders of magnitude or more when you take building wake effects into 17 incidence 18 and when you take into account 19 account. And the second thing that's come up Savannah River Site which is 20 at under discussion in that SEC certainly, 21 and if I

- 1 recall also at other places -- at least one 2 other place -- is you have activities on the 3 have fugitive emissions ground. You Savannah River Site. You have burning of 4 5 solvents. You have ground-level source terms 6 that cannot be handled in that way and workers in the vicinity of ground-level source terms. 7 And Т think this kind of 8 so 9 environmental dose calculation, we've at least 10 pointed out -- and you might expect that if this is the response then we'll have a second 11 12 round of discussions so you might want to consider some of our prior comments in other 13 cases in preparing your response. 14 That's helpful. 15 MR. KATZ: 16 DR. BUCHANAN: Okay. Move on to Issue number 2. That was kind of a drawn out 17 issue with four parts. So it probably is one 18 19 of the longer ones.
- Issue number 2 is interviewing the workers and from the documentation I could

1 find, the workers at Weldon Spring did not 2 have the benefit of the egress monitors. 3 other words, they weren't either surveyed with pancake probes or something when they left, 4 they didn't have a monitor to stick their 5 6 hands in back in the '50s. And so they 7 essentially combined with the contamination in 8 the work area left unmonitored as far 9 contamination goes.

There was some area monitoring to keep dust levels down and that sort of thing at Weldon Spring. But as far as I could find, there was not a routine set egress monitoring that either checked them when they left the production area and went into the cafeteria or the offices or whatever, which would of course track contamination around. And also when they got out in the parking lot and left for the car and went home, there was no egress monitoring.

So the workers went home with the

10

11

12

13

14

15

16

17

18

19

20

21

1 contamination on them. Sometimes they There were showers there if 2 showered. 3 There was coveralls available that wanted to. But there was no checking before 4 they wore. 5 they left. 6 And so, this is a case where I see 7 that there would be a situation where there was no dosimetry of contamination on the skin, 8 9 especially the folds of the skin around the 10 the nose, the arms and that sort of ears, thing which they could have went home. 11 Thev 12 would have had the contamination on them and got skin irradiation without any dosimetry to 13

> if they And SO even wore dosimeter at work, as bioassayed at work, what brings up the other issue is covert bioassay for certain periods. They could have had an intake from the re-suspension and the they tracked home with them. contamination And it wouldn't have been detected if they

document it.

14

15

16

17

18

19

20

21

- weren't happened to be in the queue to have
- 2 bioassay for that period of time. So that is
- 3 the concern on lack of egress monitoring.
- 4 I cannot find anywhere where it
- 5 would be documented or be able to compensate
- 6 for it.
- 7 MR. ROLFES: Okay. I know we've
- 8 taken a look at this previously. And usually
- 9 the contamination on the skin would be
- 10 visible. To have something that would impart
- 11 any external dose, you'd have to have some
- visible contamination on your hands.
- So you can come up with a bounding
- 14 value of the time that that material resides
- 15 in the skin folds. First of all, the
- 16 individual would have to have a cancer
- 17 diagnosed for our program. They would have to
- 18 have a cancer diagnosed in that particular
- 19 location for us to consider something like
- 20 that.
- So for example, an individual has

1 a cancer diagnosed on their hand, and they 2 think contamination could that have 3 contributed to that cancer. You can come up with a bounding value of the amount of uranium 4 5 that would get stuck on your hand, for how 6 long it would get stuck there, and come up with an estimate of the dose received by the 7 8 skin in that particular little area. And 9 typically, that dose value is trivial compared to the direct radiation from handling large 10 11 pieces of uranium such as ingots or aged 12 uranium materials. Yes, this is Stu. 13 MR. HINNEFELD: I've got a little different perspective on 14 this has come up 15 this. Ι mean, at other 16 places too and how you deal with this possible skin contamination without evidence of such. 17 18 So I think it's something we haven't really 19 resolved yet. But something that we have and has to be worked on because it's 20 come 21 elsewhere.

- DR. BUCHANAN: I was thinking more
 of around the neck and the ears and stuff.
- 3 That's where you see most cancer --
- 4 MR. HINNEFELD: Wherever,
- 5 wherever. The situation is the same. In a
- 6 lot of the uranium plants for the DOE quite
- 7 frankly didn't use egress monitors until my
- 8 career in some places. And I'm pretty old but
- 9 I'm not quite that old.
- 10 And so, certainly there's question
- of these uranium plants and the possibility
- 12 for skin contamination that would not have
- 13 been detected and how are we going to deal
- 14 with that issue programmatically because of
- 15 once you start speculating that there was
- 16 contamination there, there's no reason to stop
- 17 until you have a compensation on your skin --
- 18 there's just no -- we'll have to see if
- 19 there's a reason to stop it. I guess we
- 20 haven't figured one out yet.
- 21 MR. ROLFES: The one other thing

also I guess we should consider is the odds of 1 2 contaminating body part without а 3 contaminating your badge. If you're exposed truly to a large quantity of uranium in the 4 workplace, it's not going to be localized to 5 6 one point on your body typically -- possibly 7 if you're doing just your hands direct But if you're rolling around in the 8 handling. 9 mud or whatever, it's going to get distributed 10 throughout your body -- all over your body. 11 And so it'd be difficult to not get any of 12 that on your badge. So in many cases, the badge could record that contamination that was 13 14 also deposited on other parts of your body. 15 MR. HINNEFELD: No, we're not going to solve it here today. 16 Stu, this is John. 17 DR. MAURO: Ι agree with you completely that -- and this 18 19 issue has come up -- and I recall the very first time was a review of I believe it was 20 OTIB-17 which is the nonpenetrating radiation. 21

- 1 And that goes back maybe four years.
- This is a difficult problem. Jim
- and I have discussed it at other work group
- 4 meetings and other venues. And I do not
- 5 believe I've seen an occasion where that
- 6 particular exposure scenario -- the one that
- 7 was just described by Mark -- you know, where
- 8 you do -- run bar skin to see what possible
- 9 dose.
- 10 So yes, this has been a
- 11 longstanding issue. And I think it's an
- 12 important issue for those people with skin
- 13 cancer, especially on exposed surfaces. That
- 14 definitely needs to be addressed. And I think
- it is a global issue.
- DR. BUCHANAN: I'm going to move
- on here.
- 18 Issue 3 on page 4, and this is the
- lack of worker data for 1967. And one reason
- 20 I went through the first summary was it just
- 21 illustrates the thought in 1967, the petition

- 1 was through '67. Well, the petition was
- through '66 and NIOSH evaluated through '67.
- And a lot of this applies to '68, but it's not
- 4 really under the SEC.
- 5 And on December 31st of 1966, the
- 6 plant essentially shut down. And then in '67,
- 7 apparently the Mallinckrodt safety and health
- 8 physician was not present. AEC was not
- 9 present. And there was apparently -- and this
- 10 is kind of a gray area -- some sort of
- 11 contractor, subcontractors and third- and
- 12 fourth-level contractors doing work at the
- facility to revamp some of the buildings for
- 14 herbicide production. And this is where one
- 15 of the major worker concerns are is that
- during this period, there wasn't a consistency
- in any radiation protection.
- 18 One worker described the job of
- 19 going into one of the buildings, digging up
- the brick floor and handling the uranium salts
- 21 and yellow cake by hand, scooping it out

1 without any protective clothing. He wore 2 boots, had him leave the boots there for a 3 while and then he could wear them. And after a while, they let him leave with the boots. 4 Some of the people around him he described as 5 6 wearing moon suits which I assume is the anti-7 contamination. That's apparently a different contractor. And so there did not appear to be 8 9 any oversight of health physics practices there in '67. 10 Looking through 11 the records. 12 looked through records to see if I could find any dose records for '67. And I couldn't find 13 I might have missed them, but the ones I 14 looked at, I couldn't find any. People that 15 worked there in '66, I looked at some to see 16 if claims that worked there in '66, '65, there 17 was records for them. At '67, there was just 18 19 a blank wall. There were no records for '67. And what complicates the issue is 20 that this wasn't like the operations period, 21

- 1 it wasn't like the later clean-up period in
- the '80s, and so kind of what SC&A's question
- is is, what are we going do about 1967 because
- 4 the situation was different than any of the
- 5 other periods.
- 6 MR. HINNEFELD: Was the site under
- 7 the Army's control or DOD's control in 1967?
- 8 MR. ROLFES: Yes.
- 9 MR. HINNEFELD: It transferred to
- 10 the Army in '67, right, for work? And the
- 11 Army was doing this work?
- 12 MR. ROLFES: Correct. Correct.
- 13 You have to take a look at the specific
- 14 workers that you're referring to, but the
- production period ended December 31, 1966.
- 16 There could be potentially some
- 17 AEC employees that entered this site during
- 18 1967. However, it was officially transferred
- 19 from the DOE to the Department of Defense back
- to the Army in 1967. So if an individual's
- 21 doing Army work, essentially it's not covered

- 1 under this program.
- 2 MR. FITZGERALD: Was the intent of
- 3 having '67 included in --
- 4 MR. ROLFES: In case --
- 5 MR. FITZGERALD: -- case there
- 6 were AEC workers that came back?
- 7 MR. ROLFES: Correct.
- BUCHANAN: How do we know?
- 9 And a petitioner -- and I mean, the workers
- 10 addressed this directly to me. How do we know
- 11 what the cut-off line is? Do we have any
- 12 documents to show that there was no workers
- employed under the AEC contract there in '67
- 14 and '68?
- 15 MR. ROLFES: We have
- 16 documentation. And there's documentation on
- 17 the DOE website showing that the DOE handed
- 18 the site over to the Department of the Army in
- 19 1967. I don't recall the specific month, but
- 20 I believe Mel might be able to provide that if
- 21 he heard my question.

- 1 Mel, do you recall the month that
- the Department of Energy handed the control of
- 3 Weldon Spring Plant back over to the
- 4 Department of the Army?
- DR. CHEW: Mark, I do not recall.
- I think the data is available. I just don't
- 7 have it in front of me here.
- 8 MR. ROLFES: Okay.
- 9 MR. FITZGERALD: If there was an
- 10 AEC worker for whatever reason that came back
- on site, it would not be a Weldon Spring
- 12 worker per se. It'd be covered under another
- 13 site.
- 14 MR. ROLFES: That's possible, yes.
- 15 We'd have to take a look at --
- 16 MR. FITZGERALD: That's why you
- 17 left the door open?
- 18 MR. ROLFES: Right.
- MR. FITZGERALD: Okay.
- 20 MR. ROLFES: There was uncertainty
- there. So that's why we included it.

1	MR. FITZGERALD: Okay. My
2	understanding is the remediation work was done
3	by the Army because they weren't so they
4	hired a bunch of contractors to do that
5	mediation work. Because I was at a worker
6	meeting in St. Louis for Weldon Spring
7	workers, and they were describing this very
8	clearly. And it's one of the injustices of
9	the program is, I'm sorry, once it went to the
10	Army, you're not in this program anymore. If
11	your contract is with the Army, you're not
12	covered.
13	MR. ROLFES: Okay. That helps
14	too. I think the confusion was why the ER
15	didn't go into '67. You're saying, just to
16	make sure, that it covered those that might
17	have. Correct.
18	DR. BUCHANAN: Would it be
19	possible so that I could pass that on to
20	when they question me of the document that
21	shows that it was transferred to the Army? Do

- 1 you have it?
- MR. ROLFES: Yes. We can get a
- 3 reference for you.
- DR. BUCHANAN: That would be
- 5 helpful because that's a real problem there.
- 6 DR. MAURO: This is John. I have
- 7 a question.
- 8 If I recollect, during the
- 9 determination and you move into let's say the
- 10 residual period or the D&D period, there's a
- 11 distinction between DOE facilities and AWE
- 12 facilities where I believe in the case of DOE
- facilities, this post-operations period does
- 14 not come into play, but it does in AWE period
- 15 -- AWE sites. Now I believe this is a DOE
- 16 site.
- 17 MR. KATZ: Right. So you're
- 18 correct about all that, John.
- DR. MAURO: And just for my
- 20 edification, what's the rationale for that
- 21 distinction?

- 1 MR. KATZ: It's legislative, John.
- 2 MR. HINNEFELD: What the law
- 3 wrote.
- DR. MAURO: Okay. So now is this
- 5 year 1967 considered to be part of the post-
- 6 operation period for Weldon? And if so,
- 7 doesn't that take it off the table?
- 8 MR. KATZ: When the facility was
- 9 transferred to the Department of the Army,
- 10 it's no longer a covered facility. It's no
- 11 longer covered under the statute.
- 12 DR. MAURO: Even if it wasn't --
- 13 stay with me for a minute -- and it represents
- 14 post-operations, does that --
- MR. KATZ: No.
- DR. MAURO: I just want to
- 17 understand this.
- 18 MR. KATZ: No. So a DOE facility,
- 19 as long as it's a DOE facility, it's covered
- 20 regardless of whether they're operating or
- 21 whether they're in a nonoperating --

1 DR. MAURO: I got you. So the 2 distinction between operations and post-3 operation applies only if the DOE operation And I guess this idea of residual terminated. 4 5 period not applying to a DOE facility is 6 because DOE is longer running no that 7 facility. 8 MR. KATZ: Right. So Ι mean, 9 again I don't want to speak to legislators' 10 intent, but it makes sense to me with the AWEs that they're only covering during the residual 11 12 period contamination that's clearly part of the work that was done during the operational 13 So that's what it's about with AWEs. period. 14 15 DR. MAURO: Okay. 16 MR. KATZ: In the case of DOE, it 17 doesn't really whether matter they're operating or they're in a nonoperating mode. 18 19 It's a DOE facility. It's covered. 20 It's covered. DR. MAURO: So the residual period would count if in fact it was 21

- 1 still under --
- 2 MR. KATZ: Right. As long as it's
- a DOE facility, it's covered.
- DR. MAURO: I got you. I
- 5 understand. Okay. That's helps out.
- 6 So it sounds like the issue here
- 7 has to do with 1967 and whether or not it's a
- 8 covered period or not.
- 9 MR. KATZ: Exactly.
- DR. MAURO: Okay.
- MR. KATZ: And then at some point,
- 12 it clearly, according to everything that's
- 13 been said here, it was transferred to the
- 14 Department of the Army.
- 15 DR. MAURO: Got it. Okay. Thank
- 16 you.
- 17 MR. FITZGERALD: Essentially you
- 18 could have just ended it at the end of '66.]
- 19 mean, I don't quite see the -- I'm struggling
- with this rationale for including '67 because
- even if somebody came back, they'd be covered

- 1 under a different facility anyway. I think
- 2 that's why everyone's --
- MR. HINNEFELD: They're not at a
- 4 covered facility when they're at Weldon
- 5 Spring. Once it turned over to the Army,
- 6 regardless of whether they were with AEC or
- 7 not.
- 8 MR. FITZGERALD: You're
- 9 effectively talking about the end of `66 as
- 10 being the ER.
- MS. HOWELL: Yes.
- DR. BUCHANAN: Okay. Now we want
- 13 to clarify that the whole facility was
- 14 transferred, not just that plant.
- Was the site, the pits and the
- 16 quarry transferred?
- 17 MR. ROLFES: The quarry was not.
- 18 And I'll read from the Energy Employees
- 19 Occupational Illness Compensation Program, DOE
- 20 page -- the worker advocacy page.
- 21 The Weldon Spring Plant -- let's

1 get to the part that we're discussing -- in 2 1967, the AEC transferred most of the acreage 3 including the chemical plant back 4 Department of the Army. The AEC did, however, retain possession of the raffinate pits and 5 6 quarry on approximately 50 acres. The AEC did 7 not have any contractors performing work on 8 this land again until August of 1975 when the 9 AEC contracted with National Lead to perform 10 environmental monitoring the pits on and 11 And it goes on. quarry. 12 So what we can do is provide some documentation of the data feed exchange back 13 over to the Army. And this is certainly 14 something that we would consider if we have an 15 individual that has employment during 1967. 16 The Department of Labor would take a look to 17 see if that employer is a covered employer in 18 19 contract to the Department of Energy. if that individual was on site and had covered 20

employment, we would receive that from the

21

- 1 Department of Labor and account for that in
- 2 our dose reconstruction.
- I don't have a feeling. I haven't
- 4 looked at all of the claims to determine how
- 5 many cases we might have received with
- 6 employment during 1967.
- 7 MS. HOWELL: Can I ask a
- 8 clarifying question?
- 9 The DOE covered period for the
- 10 site, according to their website it still says
- 11 through '67. Has that been modified and the
- 12 website not updated? Or --
- MR. ROLFES: Well, there was a
- 14 production period up until December 31, 1966.
- 15 And it wasn't until 1967 that DOE handed the
- land back over to the Army.
- 17 MS. HOWELL: So was it January 1?
- 18 MR. ROLFES: Exactly. That's --
- 19 MS. HOWELL: Well, I guess I'm
- 20 trying to understand here -- I mean,
- 21 ultimately this will wind up being a question

- that the Department of Labor is going to have
- 2 to resolve. But I'm a little confused about
- 3 this apparent discrepancy in when DOE had the
- 4 covered period ending versus what you're
- 5 saying DOL is saying and what this information
- 6 is. Because we need to know what the proper
- 7 bounds of the NIOSH inquiry are and what the
- 8 bounds for any SEC might be, et cetera.
- 9 So I think that this is something
- 10 that we might want to resolve because there
- seems to be a discrepancy between DOL and DOE,
- 12 and ultimately DOL would probably be the party
- 13 having to resolve that.
- DR. CHEW: Mark, this is Mel.
- 15 The Weldon Spring Site Profile
- 16 description says that it was turned over to
- 17 the Army in August of 1967. David Harrison
- 18 just emailed me that.
- 19 We'll need to confirm that, making
- 20 sure that that's accurate. But that's what's
- in the Weldon Spring site description right

- 1 now.
- MS. HOWELL: Okay. So we should
- 3 clarify that, and then we should also clarify
- 4 what the DOL and DOE the covered period should
- 5 have been. It went through August of '67? I
- 6 mean, we need to be clear about this.
- 7 DR. BUCHANAN: So that if the
- 8 issue resurfaces for a person that worked
- 9 there until August of '67 --
- 10 MR. HINNEFELD: Yes, if anybody
- 11 did.
- 12 DR. BUCHANAN: And I find five
- 13 claims that had '67 as an employment date.
- MR. HINNEFELD: Okay.
- DR. BUCHANAN: I think it was
- 16 five.
- 17 Okay. So we move on. And so for
- 18 each in 3, we're going to clarify the exact
- 19 date and document -- provide a document of
- 20 that transfer and then look at the claims and
- 21 see what's going to be done that had

- 1 employment date in '67. Even if they're just
- 2 getting into the month of January or
- 3 something, we still have to address it.
- 4 MR. KATZ: Sure. And I wonder if
- 5 you need to clarify -- I mean, the
- 6 remediation-type work that you were talking
- 7 about, that's work that would have been done
- 8 under the Army, then you can assume that it
- 9 occurred then after August, I guess, because
- 10 it wouldn't have occurred --
- 11 MR. HINNEFELD: We'll have to
- 12 figure it out.
- MR. KATZ: Yeah.
- MR. HINNEFELD: We'll have to see
- 15 what we can find out.
- DR. BUCHANAN: Okay, so --
- 17 MR. FITZGERALD: Anyone need a
- 18 break?
- 19 MR. KATZ: There's at least one
- 20 head nodding here, so let's take a --
- 21 CHAIRMAN GIBSON: Ten, fifteen?

- 1 MR. KATZ: Fifteen, so at quarter
- of, by my watch, about --
- 3 CHAIRMAN GIBSON: We will restart,
- 4 and I'm just going to put the phone on mute,
- 5 but I'm not disconnecting it.
- 6 (Whereupon, the above-entitled
- 7 matter went off the record at 10:30 a.m. and
- 8 resumed at 10:47 a.m.)
- 9 MR. KATZ: Okay. Welcome back.
- 10 We're reconvening after a short break. This
- is the Weldon Spring Work Group, the Advisory
- 12 Board on Radiation and Worker Health.
- 13 And carry on.
- 14 DR. BUCHANAN: Okay. This is Ron
- 15 Buchanan. And we're looking at SEC issues,
- and we've went through 1, 2, 3 and we're ready
- for number 4 on page 4 of the handout.
- 18 And this is concerning radon and
- 19 thoron determinations.
- 20 MR. ROLFES: Ron, I'm sorry. I
- 21 had one quick question.

- 1 You had mentioned some interviews
- 2 with workers. Have you provided those
- 3 interviews to us yet?
- DR. BUCHANAN: Yes. They're on
- 5 our site profile review --
- 6 MR. ROLFES: Okay.
- 7 DR. BUCHANAN: -- that was issued
- 8 in February of '09.
- 9 MR. ROLFES: Okay. Thank you.
- 10 DR. BUCHANAN: They're an appendix
- on that.
- MR. ROLFES: Thanks.
- DR. BUCHANAN: Okay. So issue 4
- is radon and thoron. Okay.
- Now as we said earlier, Weldon
- 16 Spring did not have pitchblende so they didn't
- 17 have as much radon radium and therefore radon
- 18 problems as the Mallinckrodt downtown facility
- 19 did. However, radon still does emanate from
- 20 the uranium ore. And according to the way I
- 21 understand NIOSH -- and there was no

1 measurements at Weldon Spring for radon or Thoron comes from the thorium chain 2 thoron. which was processed '63 to '66. 3 It has a short half-life -- thoron does -- about 55 4 So it isn't around as long and it 5 seconds. 6 doesn't penetrate as greatly as the radon. 7 But it is still an issue. And so in A and B there of issue 4, if A is radon, B is thoron 8 9 -- similar issues with them. 10 There were no measurements. There 11 was measurement at the downtown facility, but 12 you can't extrapolate them out here because it was a different facility and different ores. 13 And so what I understand been proposed is that 14 they use the throughput of uranium, and then 15 there's a certain emission from the uranium 16 fraction -- of the radon that escapes. 17 18 Ι understand this And the way 19 modeling here is that it was most prevalent in one of the locations. And so it was assumed 20 that the radon that did come off was captured 21

1 in the hood, and so the workers inside the 2 building were not exposed to that radon. went out the ventilation, went out I think a 3 ten-meter stack and then dispersed, and used a 4 5 simple ground model calculate to its 6 concentration in number of curies that was 7 emitted and then its concentration. And it was assumed it was equal 8 9 inside and outside and the breathers -- the inside 10 workers would breath that concentration, and using an equilibrium factor 11 12 of .5 for inside and .3 for outside. And this would be a sign then as the radon intake. 13

> And so I'd like for Arjun to speak to this. I did look at the measurement that was done at the downtown site that showed that the indoor and outdoors weren't equal. It's four times greater inside than inside. Now this couldn't be extrapolated directly to Weldon Spring, but is an indication that equal inside and outside should be investigated

14

15

16

17

18

19

20

21

- 1 further.
- 2 And so since Arjun had worked on
- 3 radon equilibrium at other sites, I'd like for
- 4 him to speak to this.
- DR. MAKHIJANI: Yes. I'll address
- 6 it briefly. Actually, John, if he's still on
- 7 the line, has addressed it more than me.
- 8 But I think that the dispersion
- 9 modeling would be an issue, especially since
- 10 it's not validated by any data points. I
- 11 think the fact -- do we have -- just as a
- 12 factual thing because I haven't looked at the
- 13 source data -- do we have kind of concentrate
- 14 composition information in regard to the
- 15 radium source term there?
- MR. ROLFES: There really wasn't a
- 17 significant radium source term.
- 18 DR. MAKHIJANI: Yes, I'm aware
- 19 that concentrates don't have most of the
- 20 radium stripped from them. But they don't
- 21 have most of the thorium-230 stripped from

- them. That was an issue at Fernald anyway.
- 2 And I just wanted to know whether
- 3 we have some data on the concentrates as
- 4 regards -- because there is some thorium. If
- 5 you look at the cold metal oxides in silo 3, I
- 6 think at Fernald, there's a radium source term
- 7 there. It's not zero.
- 8 MR. ROLFES: Very, very small.
- 9 Very, very small.
- DR. MAKHIJANI: Well, it's not
- 11 equilibrium with thorium-230. That's for
- 12 sure. I don't remember the numbers.
- But it might be useful to have a
- 14 radium source term that's specific to the
- 15 site, I think, especially given the recent
- 16 history of modeling in regard to radon and a
- 17 lot of issues have come up. They've come up
- 18 at Linde. They've come up at Texas -- right,
- 19 John -- Blockson. I think this looks like a
- 20 lot less rigorous than the scrutiny that's
- 21 been given and the rigor with which we've

- 1 tried to approach radon at other sites.
- 2 MR. HINNEFELD: Help me understand
- 3 why radon is an issue at Weldon Spring if they
- 4 never got ore.
- 5 DR. MAKHIJANI: The concentrates
- 6 do contain some radium. And that's why my
- 7 first question was if you have some
- 8 characterization of the kind of concentrates
- 9 and there isn't really radium in it and we
- 10 know that because the source term has
- 11 characterized it, then the issue will go away.
- 12 But we know that some of these
- 13 concentrates contain non-trivial amounts of --
- in my opinion, non-trivial amounts of radium,
- 15 but much less than would be in equilibrium
- 16 with thorium-230.
- 17 MR. HINNEFELD: Well, the examples
- 18 you all cited about radon being an issue or
- 19 sites where radium was at least a readable
- 20 component of material that was handled, they
- 21 had ore at Linde and radium is a reasonable

- 1 component of the norm in the phosphate --
- DR. MAKHIJANI: Right.
- 3 MR. HINNEFELD: -- since in all
- 4 the radioactivity at the phosphate plants like
- 5 Texas --
- 6 DR. MAKHIJANI: And I agree with
- 7 that.
- 8 MR. HINNEFELD: So in all those
- 9 cases, radium was a significant portion of the
- 10 radiological source term. And I think my
- 11 going and belief -- now maybe I'm mistaken
- 12 here -- is that concentrate, since you remove
- 13 the radium in the concentrate, then you have
- to grow the radium back in from the thorium-
- 15 230.
- DR. MAKHIJANI: It won't grow back
- 17 in.
- 18 DR. MAURO: Stu, this is John. I
- 19 could help out a little bit here.
- 20 I've reviewed a couple of AWEs and
- 21 cases where the concentrates which are

1 primarily U308, they've been separated, sometimes carry over with it small amounts of 2 3 thorium-230 and radium-226. And I agree with you -- and it's variable depending on how good 4 a job is done in creating the concentrates. 5 6 Now that being said, I guess the 7 I could see any radon being only way concern is, okay let's say you could say well, 8 9 we know that almost all except for some small amount of radium-226 may have been removed and 10 did not show up at Weldon, but there could 11 12 have been this much. Now given that there could be a little bit of radium, the question 13 it possible that 14 is. is there's any substantive concentration of radon in the air 15 that would be of some concern. 16 17 In theory, one could argue okay, let's say that there's as much as a certain 18 amount of trace levels of 226 -- radium-226 19 associated with the yellow cake. 20 That shows up at the treatment processing at Weldon. 21

1 you've got a handle on okay, well, this is the 2 amount of radon -- construction rate of radon, 3 that would be entering the air. And again, we're back to the same old problem again. 4 Once you know that, you probably could place a 5 6 plausible upper bound on what the radon 7 might be indoor concentration making 8 appropriate assumptions regarding air turnover 9 rate and emanation coefficients, that sort of 10 thing. 11 But of course, we're back in the 12 modeling world again, a model that -- that model applied to 13 class of that class problem, SC&A's very comfortable with as long 14 as you have a pretty good idea of what the 15 16 upper bound might be on the radium-226 in your 17 yellow cake. 18 But that's the way you would come 19 at saying well, here's an upper bound on what might have been the radon concentration. 20 And if that turns out to be trivial, well, I think 21

1 the problem's been put to bed.

2 Whether or not the work group and 3 the Board would agree with the strategy like that because it does in effect employ a model 4 5 opposed to direct measurements. 6 would be the first to agree that in general, 7 when we're dealing with yellow cake, we don't really think and worry too much about radon 8 9 Arjun did point out, there are except as occasions when there is a little bit of radium 10 11 that comes along with your concentrates.

DR. MAKHIJANI: Yes. And I agree said, what you Stu, in that stripping most of the radium. And sometimes you might strip essentially all of it. But concentrates is sort of different than yellow cake in that you haven't stripped all of the cake products from the ore.

And so, all I'm saying is if you can characterize the source term, it will be much simpler to deal with the issue. It might

NEAL R. GROSS

12

13

14

15

16

17

18

19

20

21

- 1 just go away, or you might be able to put a
- bound on it in a better way than what's on the
- 3 table right now.
- 4 MR. FITZGERALD: Yes. Before
- 5 getting to the modeling, the threshold
- 6 question sounds like just establishing what
- 7 the likely source term was --
- 8 DR. MAKHIJANI: Right.
- 9 MR. FITZGERALD: -- from the
- 10 concentrate. If it's negligible, then the
- issue is less. That seems to be the threshold
- 12 question, before getting into the modeling
- 13 point. Now thoron, of course, would be a
- 14 different issues --
- DR. MAKHIJANI: Yes.
- 16 MR. FITZGERALD: -- particularly
- 17 since thoron -- so, yes.
- 18 DR. MAKHIJANI: Thoron's an issue.
- 19 MR. FITZGERALD: Yes. Okay.
- 20 MR. ROLFES: If I could point
- 21 everybody up to a reference in the site

- 1 research database, we've prepared a response
- 2 in our site profile review matrix on page 2
- 3 that addresses this. And we've got a
- 4 statement in here that says, based on uranium
- 5 mass throughput and other factors from
- 6 Meshkoff, et al, 1986, an estimated annual
- 7 release of radon-222 during the operating
- 8 period was in the range of 12 to 34 curies.
- 9 Now if you take a look at this
- 10 reference I mention --
- 11 DR. MAKHIJANI: Mark, excuse me.
- 12 Which item in that response are you looking
- 13 at?
- 14 MR. ROLFES: I am looking at
- response number 1 which is on page 2 of the
- 16 NIOSH responses to SC&A comments on the Weldon
- 17 Spring Plant.
- 18 DR. MAKHIJANI: I have the
- 19 document. I just wanted the number.
- 20 MR. ROLFES: The Site Research
- 21 Database reference number for this reference

- is 72152. And it does have information on the
- 2 source term of radon at the site.
- I'll take a look to see if it also
- 4 has thoron in there. But I don't see it right
- 5 away.
- But this is a starting point for
- 7 --
- 8 DR. BUCHANAN: This is the same in
- 9 the TBD. The TBD used this model, at least
- 10 the calculations. The 1986 reference used
- 11 this same calculation in it.
- MR. ROLFES: Okay.
- 13 DR. BUCHANAN: The TBD 4 or 5 uses
- 14 this reference in the calculation of
- throughput of uranium and a certain emission
- 16 rate and a certain stack height. And then
- they calculated 12 to 34 curies released per
- 18 year. It's the same thing that I sent to you,
- 19 Arjun, earlier.
- 20 DR. MAKHIJANI: Okay. Is it
- 21 72192? I was traveling when I responded to

- 1 you. So I don't remember exactly.
- 2 MR. FITZGERALD: And this is where
- 3 he accomplished the concentrate. In other
- 4 words, all the different --
- DR. BUCHANAN: No, it just uses a
- 6 uranium throughput and assuming a certain
- 7 emission rate of radon from the throughput.
- 8 And it's all captured in the hood and goes out
- 9 a ten-foot stack. And then it would emit 12
- 10 to 34 curies a year and that would disperse
- 11 and then they'd be sucked back into the
- 12 building and be equal inside and outside and
- then working levels are calculated from that.
- 14 DR. MAKHIJANI: The dispersion
- model would be a problem the same as what I
- 16 said.
- DR. MAURO: This is John. Let me
- 18 just step in.
- 19 So are you saying that at Weldon
- the concentrates were not piled up indoors but
- 21 they were sitting in hoods? Did I

- misunderstand? In other words -- this is an
 important point.
- 3 If the reality is that any radon -- any radium, even if it's in trace levels, 4 contained in the concentrates is -- there's a 5 6 confinement system around it whereby as it's 7 emanated in small quantities, it's captured and vented. Well, then it wouldn't enter the 8 9 workplace the way I just described. What I'm it 10 hearing is would be exhausted. Now certainly it could come back in again from 11 12 outdoors. But that changes the whole picture
- ROLFES: The hood I believe 14 MR. that you're referring to would have been the 15 16 air ventilation system above the acid 17 digestion tank. And that was where the radon was assumed to be liberated from and vented up 18 19 a stack.

and makes it even a more remote issue.

DR. MAURO: Okay. So you're saying that the radon comes -- see, I guess I

NEAL R. GROSS

13

1 had a little bit different conceptual model.

2 You've got concentrate. The

3 concentrate if it has any radium in it, will

4 be exhaling radon all the time whether it's

5 been digested or not. Certainly if it's

6 digested, then you're breaking up the matrix

7 in a way that even more radon could be

8 released.

9

10

11

12

13

14

15

16

17

18

19

20

21

But even if it's just sitting --I'm visualizing a pile or 55-gallon drums of concentrate. And they're broken open. they're all sitting in some kind of confined area with ventilation exhaust control, then the radon, even if it's small quantities -don't talking about get me wronq, we're concentrates so we're not expecting very much radium in there but there might be a little Any radon whether it's digested or not bit. will escape to a certain degree. And if it's direct access to the general working

environment, there will be some airborne radon

in the general working environment.

2 Τf doesn't -- if it's it 3 captured by some kind of ventilation system that is a hood over it, well, then that radon 4 it sort of escapes will be captured and 5 6 really not enter the breathing zone of the 7 working environment. And that does change the picture a bit. And of course, if you folks 8 9 could show that there really wasn't any radium first 10 there in the place because the concentrates were of a quality, well, then the 11 12 problem also greatly diminishes.

So the only reason I jumped in here is when I heard stack releases, I just assumed that was general exhaust from the working area. But you're saying that no, that was exhaust from hoods. And then I thought maybe think about this differently in concept.

MR. FITZGERALD: Well, going back again, I think this still comes down to a source term -- a Weldon source term estimate.

NEAL R. GROSS

13

14

15

16

17

18

19

20

21

- And I think what Mark's pointing out is we 1 2 actually do have some estimation that confirms 3 there was radium. The only question I think in my mind is whether that calculation would 4 5 encompass the concentrates or not. It sounds 6 like they just took a kind of a simple feed in 7 of uranium and just came up with a calculation over time. 8 9 And the question is is that source 10 12 to 34 curies, would that in fact term. encompass the probably small contribution from 11 12 these things like concentrates or not. So this is actually a reasonably good number. 13 Then the other question is the one 14 I think that's raised in the matrix which is 15 we only have the emissions number from the 16 Does that necessarily reflect what's 17 stack.
- DR. MAURO: Yes.

in the workplace itself?

MR. FITZGERALD: And I think
that's a pretty good question. I would think

NEAL R. GROSS

18

that if this is the off-gas and the potential 1 concentrations -- and this is kind of 2 3 that could keep coming up in this modeling with the Board is can you show us or 4 demonstrate how you would know that that is 5 6 bounding or not. And I think it'd be pretty difficult to show that the emissions from the 7 8 stack would be bounding the actual workplace. 9 So Ι think that's the question. 10 there's a unique source term for Weldon, 11 does this range encompass that source term if 12 in fact the source term is for the workplace not for the environment? And I think someone 13 said earlier can we get a source term for 14 Weldon that we can feel comfortable with. 15 And I think at this point, there's some questions 16 17 around that. We'll definitely 18 DR. MAKHIJANI: 19 look at the document. I mean, that should be part of what to do, I guess. 20

DR. BUCHANAN:

21

I sent that to you.

- I went through the whole calculations. 1 And 2 It's a model that so much is its assumptions. 3 emitted from a certain uranium throughput. understand that it's vats where the digesting 4 the concentrate in acid. And then they have a 5 6 few open. It's not inside a glove box or 7 something like that. It's in a big room with vats and they have these hoods over them. 8 9 They exhaust to the stack.
- 10 FITZGERALD: And this MR. I would think that if you 11 pretty large-range. 12 took the upper part of that range, the only question would be, well, how can you translate 13 that to the workplace, know that you have a 14 bounding for 15 number the actual workers themselves around those vats, not necessarily 16 17 in the stack, right.
- DR. BUCHANAN: Yes. Because the 19 1986 reference, now what it calculates is the 12-34 curies being emitted.
- 21 MR. FITZGERALD: Being emitted.

1 DR. BUCHANAN: And it doesn't say 2 It doesn't go any further as far as anything. 3 the intake. Then there's assumptions made on 4 how that then circulates back to the workers 5 6 inside the building and outside the building. 7 Ι MR. FITZGERALD: Because remember these other sites that we've had 8 these lengthy debates before the Board. 9 Ιt 10 was all predicated on how can you come up with this search model within the building itself. 11 12 And those were lively exchanges. I can't imagine that if this were a stack emission how 13 we could backtrack that into the workplace and 14 argue that it's bounding. So I think that's 15 16 probably the biggest issue. Well, I think we 17 MR. HINNEFELD: have the essence of the finding --18 19 MR. FITZGERALD: Yes. -- is the essence 20 MR. HINNEFELD: of the finding. 21

1 MR. MORRIS: Would you say why you 2 think it couldn't be bounding. This is Robert 3 Morris. FITZGERALD: No, I think you 4 MR. 5 would start to get into a question of whether 6 or not the ventilation, the collection hoods 7 and what have you were 100 percent efficient 8 which of course, I don't think that would 9 necessarily be the case. You'd have workers 10 around acid. I think you would have to argue 11 that yes, in those days if you had 12 efficiency of 60, 70 percent, that's pretty But you would still have perhaps 13 damn good. concentrations of radon. And it's not clear 14 to me that that necessarily would be bounding. 15 16 You'd have to at least come up with some estimate of what the collection efficiency was 17 of the --18 So would you disagree 19 MR. MORRIS: we took that first term and 20 that if pushed it inside the facility in a box model 21

- that we couldn't be bounding with that?
- 2 MR. FITZGERALD: I don't know.
- 3 MR. HINNEFELD: Robert, we need to
- 4 have this conversation ourselves.
- 5 MR. MORRIS: Okay.
- 6 MR. FITZGERALD: But I think that
- 7 gets to the root of the issue that needs to be
- 8 answered I think. That's what we're saying.
- 9 DR. BUCHANAN: Yes. Two reasons
- 10 is the source term and then the inhalation
- 11 concentration. And that goes with radon part
- 12 A and thoron part B.
- 13 DR. MAKHIJANI: I think that
- 14 source term is much more important.
- The thoron -- you're processing
- 16 thorium there. You've got thorium decay
- 17 products there. So -- yes.
- DR. MAURO: I've got a question on
- 19 thorium-232. Was that ore unlike the
- 20 concentrates of the uranium where it's
- 21 primarily uranium oxide of some form? The

- 1 thorium-232 issue that we're talking about in
- thoron, did they process ore? Therefore of
- 3 course you'd have thoron. Or was it also
- 4 separated thorium?
- MR. ROLFES: No, this wasn't ore.
- 6 It wasn't like a monazite sand for example.
- 7 It was I believe received as thorium nitrate
- 8 tetraydrate -- TNT.
- 9 DR. MAURO: Okay. And so the only
- thoron you would get is the radium-228 had the
- 11 five-year half-life. So if it was somewhat
- 12 aged, you might grow in a little radium-228
- and therefore have thoron. So I was wondering
- if you got a feel for why is there thoron
- 15 there. And is the thoron there because it was
- 16 ore? Or is the thoron there because the
- 17 thorium-232 was somewhat aged? And it doesn't
- 18 take that long. I mean, it doesn't take
- 19 thousands of years before they're -- unlike
- 20 the radium-226. The radium-228 has a
- 21 relatively short half-life of five years.

in principle, you could 1 2 some radium-228 in. And between the time the 3 thorium was separated and shipped and maybe have a thoron coming in. Do you know offhand 4 which of those we're dealing with here? 5 6 MR. HINNEFELD: It's the second, I 7 think, that you described, John. When you have a thorium product, if it has much age on 8 9 it since it was chemically purified, you're 10 going to have some thoron generation that's going to -- it becomes an issue a lot quicker 11 12 than radon-220. 13 DR. MAURO: I got it. Okay. That's helpful. 14 Good. Thank you. I believe that's 15 HINNEFELD: MR. the situation we're talking about. 16 Thorium-228 17 **BUCHANAN:** Yes. DR. has a half-life of 1.9 years. 18 So it can go 19 fairly -it doesn't 20 MR. HINNEFELD: Yes,

NEAL R. GROSS

And it doesn't have to go to

21

take a lot.

- 1 equilibrium. You've just to get a --
- DR. MAURO: Yes. Growing in.
- 3 MR. HINNEFELD: You can get some
- 4 growing in and you're starting to generate
- 5 thoron.
- 6 DR. MAURO: You know what? Ron
- 7 just made a very important point. That's
- 8 right. When you separate thorium, you get the
- 9 thorium-232 and one of the daughters. But the
- radon comes off the radium-228, doesn't it?
- DR. BUCHANAN: Right.
- 12 DR. MAURO: And that has a five-
- 13 year half-life.
- 14 DR. MAKHIJANI: No. Radon will
- 15 come off of the thorium-228.
- MR. HINNEFELD: You see, when you
- separate the thorium, you get the thorium-228
- 18 with the -- you can't separate the two
- 19 isotopes. So you've go 228 -- thorium-228
- 20 there. The radium-228 Ron says has like a
- one-point-something year half-life.

- DR. BUCHANAN: The thorium-228 has
- 2 a 1.9-year half-life.
- 3 MR. HINNEFELD: What's the radium?
- DR. BUCHANAN: The radium has a 3-
- 5 day -- 3.6-day half-life.
- 6 MR. HINNEFELD: Radium-228?
- 7 DR. BUCHANAN: 224.
- 8 MR. HINNEFELD: Okay. Right. It
- 9 goes to 224. It goes from thorium-238 to
- 10 radium-224, which has a very short half-life.
- DR. BUCHANAN: A couple days.
- 12 MR. HINNEFELD: So it's the one-
- year half-life of thorium-230 or 228 --
- DR. BUCHANAN: Right.
- DR. MAURO: Okay. That's the
- 16 driver. Okay?
- 17 DR. MAKHIJANI: It will take a
- 18 couple of months of sitting --
- DR. MAURO: Is that all?
- DR. MAKHIJANI: Because thorium-
- 21 228 are 1.9-year half-life. So after a couple

- of months, you're --
- 2 MR. HINNEFELD: Start to see it --
- 3 DR. MAKHIJANI: -- you'll see it.
- 4 DR. BUCHANAN: Any further
- 5 discussion on that?
- 6 MR. KATZ: No, you can move on.
- 7 DR. BUCHANAN: Okay. Another
- 8 issue which -- it's 5 -- which is recycled
- 9 uranium. And the ore concentrate that came in
- in '57 through '60 supposedly did not have
- 11 recycled uranium. Recycled uranium of course
- 12 comes from uranium that's been recycled, taken
- from a reactor and tried to re-use the uranium
- 14 -- unfortunately this has some byproducts with
- it -- that came to light and in year 1999, DOE
- went and did a study to try to find where this
- 17 came from and where it flowed to.
- 18 And in 1961 -- and this is a two-
- 19 part issue; one I'm sure is resolvable -- it
- 20 is the year that Weldon Spring started
- 21 receiving recycled uranium. From what I can

1 from ' 57 through '60, there see was no 2 indication of recycled uranium being resided at Weldon Spring. I don't have any smoking 3 But now in '61, documents qun saying it was. 4 5 start referring to it. 6 However, in the TBD and in the ER, 7 there's a mixture of terms -- after 1961, 8 after 1962 -- and those sort of terms which 9 are an inconsistency in the date that we're 10 supposed to start using recycled uranium at 11 Weldon Spring. And I'm sure that that's 12 resolvable. Just need to look at that and get those consistent. 13 And also, I would like to see a 14 reference that says that Weldon Spring didn't 15 start receiving recycled uranium until 1961. 16 probably 17 I'm that's available. Ι sure couldn't find it. It was really stated in the 18 19 Fernald document or in DOE 2000. However, I didn't read all of DOE 2000, because it's 1200 20

pages long, looking for it. But I do think we

21

- need to set a documented date on when recycled
- 2 uranium was received at Weldon Spring.
- I did go through the
- 4 recommendations in TBD 5 and the ER looking
- for how they planned on finding the recycled
- 6 uranium -- the first issue or the start date.
- 7 The second issue is the use of the bounding
- 8 number. If you decipher through Fernald's TBD
- 9 5 and look at their conversion factors, it
- 10 drops out for plutonium -- of course, the key
- issues that we have is the recycled uranium
- 12 contained trace amounts of plutonium,
- 13 technetium and neptunium or the most
- 14 significant amounts of some U-236.
- 15 So I looked at Fernald's TBD 5.
- 16 And they recommend 100 parts per billion
- 17 plutonium per uranium. And so, the ER though
- states on page 27, Table IV-6, an average of
- 19 2.9 parts per billion plutonium and 6.3 to be
- 20 bounding.
- 21 Okay. I have two issues. Number

1 one, would you clarify why the TBD says one 2 thing and the ER says another thing? And 3 also, I looked at some of the claims that had dose reconstruction done on them. One of them 4 had 100 parts per billion plutonium added in 5 6 correctly as the TBD instructed them. Two 7 others did not, even though it was less than 8 50 percent. And so I think probably there's a 9 lack of clarification there to the DR. 10 And so I quess the first issue is why is there a difference between the 100 11 12 parts per billion in the TBD and 2.9 and 6.3 in the ER? 13 ROLFES: The TBD for 14 MR. Okay. Weldon Spring Plant was written back in 2005. 15 And so at that time, we had adopted surrogate 16 data from the Fernald site. 17 The reason for that 100 parts per 18 19 billion default at the Fernald site was the elevated 20 because of transuranic concentrations of the Paducah flame and tower 21

1 ash which was shipped to Fernald in the late 2 '70s. And it was that that formed the basis 3 for that 100 parts per billion default even though the majority of all the other shipments 4 except for a handful were much less than 10 5 6 parts per billion plutonium on the uranium 7 mass basis. 8 The TBD that was written in 2005 9 for the Weldon Spring Plant defaulted to the 10 Fernald data of 100 parts per billion. The actual data in reviewing the Weldon Spring 11

for the Weldon Spring Plant defaulted to the Fernald data of 100 parts per billion. The actual data in reviewing the Weldon Spring site-specific data as part of this Special Exposure Cohort Evaluation Report indicated that the average concentrations were 2.9 parts per billion plutonium on a uranium mass basis and gave a 95th percentile value of 6.3 parts per billion. So the actual site data that we looked at for the Weldon Spring site indicates much lower levels of transuranic evidence.

DR. MAKHIJANI: There are site
measurements of contaminant data for Weldon

NEAL R. GROSS

12

13

14

15

16

17

18

19

- 1 Spring --
- 2 MR. ROLFES: These are based upon
- 3 the --
- 4 DR. MAKHIJANI: -- from the time?
- 5 MR. ROLFES: -- DOE 2000 report
- 6 from Weldon Spring.
- 7 DR. MAKHIJANI: So part of this
- issue is how reliable is this DOE 2000 report.
- 9 And by the accounts of people who were there
- when it was prepared, it was prepared in a big
- 11 hurry. It was prepared in response to a
- 12 scandal essentially on the front pages of
- 13 newspapers about Paducah. And it was rapidly
- 14 prepared as a mass balance. And then in 2003,
- the DOE issued another report that said, oops,
- the 2000 report was rapidly prepared.
- 17 So we've expressed a fair amount
- 18 of discomfort with the use of the report in
- 19 the Fernald case. And that issue is still on
- 20 the table. So I think the question of whether
- 21 you can use that mass balance data. So far as

- 1 I remember, the measurements are not from the
- time. The inferences are from measurements
- that were made in the '70s and '80s. Now at
- 4 Fernald at least you can say they were still
- 5 processing uranium there.
- 6 What was happening at Weldon
- 7 Spring was in a completely different time
- 8 period. And if there was recycled uranium
- 9 involved at Weldon Spring, it would have not
- 10 probably come from Paducah and tower ash. And
- 11 so I would suspect, or at least you have to
- 12 establish that it's connected to that source
- 13 term.
- 14 I would suspect that the recycled
- 15 uranium dominant source term in the DOE
- 16 complex which isn't very well treated in the
- 17 literature originated in the U Plant at
- 18 Hanford -- and I've raised this issue before
- 19 -- is when you're dealing with a U Plant at
- 20 Hanford, a set of ratios that is key to
- 21 plutonium doesn't work. It's sort of like the

- 1 raffinates at Mallinckrodt. Once you've 2 stripped the uranium, then a set of ratios of 3 thorium and radium and protactinium to uranium does work when you strip the uranium. 4 5 It's the same problem. You've 6 stripped the plutonium at the reprocessing 7 plant during the Manhattan Project. You've 8 put uranium, neptunium and fission products in 9 the tanks. And then you've taken that back 10 the uranium, fission products out and neptunium -- and you strip the uranium and 11 12 then you have entrained fission products in neptunium. 13 But you may not have any 14 significant entrained plutonium. 15 all So these other you've qot contaminants whose relationship to plutonium I 16 haven't seen established by measurement data. 17 18 And Hanford did have guidelines. But we
 - specification material. We don't have measurements. And we don't know what went to

they

had

whether

NEAL R. GROSS

don't

know

19

20

21

out-of-

- 1 Weldon Spring.
- 2 So I think these back-
- 3 extrapolations of measurements of recycled
- 4 uranium are much more problematic, at least as
- 5 things stand, at Weldon Spring than they would
- 6 be --
- 7 MR. ROLFES: I think we need to be
- 8 careful about saying we don't know what went
- 9 to Weldon Spring because there is an
- 10 evaluation of the data that was done at Weldon
- 11 Spring. And it's reference ID 11818. And
- 12 it's Health Physics Concerns for Recycled
- 13 Materials. And it's an interim report on the
- data through November 1, 1964. It has alpha
- 15 and gamma versus nuclide content.
- 16 It's a report which is 12 pages
- 17 long. It is an evaluation --
- 18 DR. MAKHIJANI: What did you say
- 19 -- 11?
- 20 MR. ROLFES: 11818. It's an
- 21 evaluation of the alpha and gamma activities

- 1 for the materials that were sent back and
- 2 considered to be recycled uranium.
- 3 DR. MAKHIJANI: From the time?
- 4 MR. ROLFES: 1964. So, yes.
- DR. MAKHIJANI: Excellent. I'll
- 6 take a look at it.
- 7 MR. ROLFES: It's an evaluation of
- 8 recycled feeds for additional health problems.
- 9 And I don't know, I don't think we need to
- 10 discuss it --
- DR. MAKHIJANI: Well, so far
- 12 what's on the table is surrogate data. And so
- if there's something else on the table, then
- 14 we'll look at that.
- 15 MR. ROLFES: It has a discussion
- of the findings with health activity and it
- mentions neptunium-237 versus 234 and 235 as
- well an analysis of actinium-227 and 231s.
- DR. MAKHIJANI: Great. If there's
- 20 substantive data from the time, this
- 21 simplifies things considerably. And then you

- 1 have the question of reprocessing of recycled
- 2 uranium and how you're treating the
- 3 raffinates. And then it becomes a more --
- 4 MR. FITZGERALD: I quess I'm a
- 5 little confused.
- 6 This document comes after -- after
- 7 the ER? I'm just trying -- why did you go to
- 8 the Fernald surrogate data?
- 9 MR. ROLFES: This document was
- 10 from the 11,800 range in the site research
- 11 database.
- 12 MR. FITZGERALD: No, I'm just
- saying you didn't choose to use that as a part
- of the recycled uranium assessment.
- 15 MR. ROLFES: Correct. I quess at
- the time just with the pressure to get claims
- done, we didn't want to go back and -- just
- 18 because of the length of the reports -- we've
- 19 got a 1,000-page report -- we felt that it
- 20 would be claimant-favorable to default to the
- 21 100 parts per billion --

- 1 MR. FITZGERALD: Right.
- 2 MR. ROLFES: -- for the Fernald
- 3 site.
- 4 MR. HINNEFELD: I think originally
- 5 the surrogate data from Fernald was used for
- 6 expedience --
- 7 MR. ROLFES: Yes.
- 8 MR. HINNEFELD: -- in the Weldon
- 9 Spring PR program.
- 10 MR. ROLFES: Right.
- 11 MR. HINNEFELD: And it definitely
- bounds what you had in that report.
- MR. ROLFES: Correct, correct.
- 14 DR. BUCHANAN: And you're saying
- that's reference 11818?
- 16 MR. ROLFES: Yes. It's 11818,
- 17 Health Physics Concerns for Recycled
- 18 Materials.
- DR. BUCHANAN: And is this where
- the 2.9 and 6.3 figures come from?
- MR. ROLFES: No, that is not.

- 1 That data is from the DOE report from 2000, I
- believe, for Weldon Spring Plant.
- 3 MR. HINNEFELD: So that question
- 4 about the quality of the 2000 report still
- 5 remains then?
- DR. MAKHIJANI: Right. So what my
- 7 suggestion would be since you're re-looking at
- 8 this stuff is that you go to the site data
- 9 that you have and then we can assess the
- 10 quality of the site data because we've raised
- 11 all these issues in another context, and
- they're still on the table and they're still
- 13 being discussed and they're unresolved at
- 14 Fernald. And then so you're kind of thinking
- 15 what's going to happen in that other arena
- 16 that will bring you back into this arena. If
- 17 you've got site data, it's much better. Then
- 18 we can look at that.
- DR. BUCHANAN: Okay. Want to move
- 20 on to issue number 6, neutron exposure
- 21 dosimetry records.

1 There at Weldon were processes 2 Springs that would create -- that's on page 8, 3 issue number 6 -- that would create potential According 4 neutron exposure. to some documents, there was NTA film issued to some 5 6 workers that were involved in these operations in a slight risk of uranium of one to two 7 percent that received during different 8 was 9 campaigns. But there results are no 10 documented. They're either in a claimant's file or they're otherwise -- see if they could 11 12 locate. And so, the question comes up if 13 potential exposure without 14 there's а records -- dose records -- to reconstruct the 15 16 dose, what do we do about that? And so 17 recently in the TBD -- and this is an area that we would like to clarify. 18 Recently in 19 the TBD, the use in Fernald measurements -one-time measurements of beta gamma -- I mean, 20 neutron gamma and do a .1 I think 21 in the

1 method. And SC&A did not agree with that in

their site review report.

- I see in the ER that it is
- 4 mentioned that the OTIB-24 would be invoked if
- 5 necessary on a case-by-case basis for neutron
- 6 dose assignment. And there was a mention of
- 7 missed dose assignment. And so at this point,
- 8 I'd just like some clarification on how
- 9 neutron dose would be assigned. It's still
- 10 TBD-6, or are you going to use OTIB-24? Or
- 11 misquotes come in when you don't have any
- 12 comeback data.

2

- MR. ROLFES: Well, I'll have to
- 14 delay a response to that. I'm not certain.
- 15 But I know for the Fernald site what we've
- 16 done in the past for workers that were
- 17 handling enriched uranium, we've applied a
- 18 neutron-to-photon ratio. From the top of my
- 19 head, that was around .3 to 1 for the 95th
- 20 percentile.
- 21 And Fernald handled higher

- 1 enrichments. It had larger quantities of
- 2 material there. So that would have probably
- 3 been a bounding neutron-to-photon ratio for
- 4 the Weldon Spring Plant.
- 5 We'll prepare a response on that
- 6 and make sure that it's addressed for the
- 7 revision.
- DR. BUCHANAN: Okay. Thank you,
- 9 Mark.
- 10 I did have one question. Do we
- 11 know -- I mean, just as a general question --
- 12 do we know that Weldon Spring only received RU
- and enriched uranium from Fernald?
- 14 MR. ROLFES: I will have to delay
- 15 my response to that once again. I --
- DR. BUCHANAN: Because that's
- 17 important. If we're going to use any of
- 18 Fernald's data, whether it's DOE 2000 or the
- 19 enriched uranium 1 to 2 percent and that sort
- of thing, we need some documentation that they
- 21 only received that material from Fernald.

1 MR. HINNEFELD: Ιf only use we 2 what now? 3 Ιf DR. BUCHANAN: we only use Fernald data for enriched and recycled uranium 4 5 6 MR. HINNEFELD: Oh, okay. 7 DR. BUCHANAN: then we need some documentation. They didn't receive some 8 9 from Hanford, they didn't receive some from 10 other places that is available through the 11 years. 12 ROLFES: on the MR. Does anyone phone perhaps -- Mel or Bob or Monica -- know 13 14 if there were uranium shipments to Spring from sites other than Fernald? 15 Mark, not that we are 16 MR. MORRIS: 17 Again, not that we're aware of. aware of. 18 MR. ROLFES: Okay. So based on 19 what we currently know, everything that Weldon Spring received would have come from Fernald 20 21 then?

- 1 MR. MORRIS: Yes, sir.
- 2 MR. ROLFES: Okay. We'll double
- 3 check on that for you.
- DR. BUCHANAN: Okay. I mean, it
- 5 would be good to have some documentation
- 6 showing that they didn't receive anything from
- 7 anyplace else.
- 8 Okay. So that was issue number 6
- 9 on neutron dosimetry.
- 10 Issue number 7 was the quarry and
- 11 raffinate pits exposures. This is kind of a
- 12 problem area in that the operators -- we might
- be able to use their data to bound, say, the
- 14 secretaries or the lawn workers or the non-
- 15 production workers so to speak at the site
- that were roaming around the site and stuff in
- 17 between admin and the plant and such.
- 18 However, the quarry and the pits are different
- 19 sources -- different source terms. And
- apparently there was not too much attention
- 21 paid to it back in the active days from '57 to

'66 and '67. 1 The quarry was kind of looked at And in fact, downtown brought a 2 as a dump. 3 junk out there from their plant -contaminated junk -- and dumped it in the pit. 4 5 other words, there In was а dump truck 6 apparently. 7 there wasn't much done And so, about characterizing it until 1970s, 1980s. 8 9 And so, I guess I have an issue with using 10 1970 and '80s data for the active period of the quarry and they were dumping stuff in it. 11 12 And also, the pits that were characterized later 13 on and now the justification in the TBD and/or the ER was you 14 grow in equilibrium of these decay products or 15 16 any measurements done later would be limiting to what was there during the production era. 17 And I agree from a scientific basis that the 18 19 ingrowth would increase. But I don't know if necessarily 20 that extrapolates to exposure

potential because after you do a measurement

21

1 and a situation -- a physical and chemical 2 component in the '80s -- wouldn't necessarily 3 reflect say the dust and the contamination stuff which was present there in dumping into 4 5 the quarry in the earlier years and the 6 condition of the pits in the earlier years. 7 And I did note that Mason did do 8 some pit characterization in the Site Research 9 Database. I think there's a '58 article in 10 there. 11 And so, that's an issue I'd like 12 to bring up is how can we extrapolate from later days back to earlier days when the pits 13 and the quarry was active as opposed to a 14 stagnant period after they had set 20 or 30 15 16 years. 17 So this is kind MR. FITZGERALD: 18 of source term question as well the 19 question of whether the source term --20 Yes, theoretically MR. HINNEFELD:

NEAL R. GROSS

there were

So

they're

okay.

21

measurements

- probably during remediation of the pits and the quarry.
- DR. BUCHANAN: Yes.
- HINNEFELD: the problem 4 MR. But 5 being that during the operation of the site 6 when they were putting things in the pits and 7 ostensibly in the quarry, then those exposures 8 -- those materials since they were essentially 9 bereft of uranium would constitute an exposure 10 that don't have uranium markers you for. whereas the operators, uranium is pretty much 11 12 the marker for the internal exposure. Is that
- DR. BUCHANAN: Yes.
- MR. HINNEFELD: Okay. Not bereft.
- 16 They were devoid. They lacked uranium.

kind of where we're at on this?

MR. FITZGERALD: And I guess just
to wrap that up, the ingrowth of the decay
products was in the time frame substantial
enough that -- I guess it's a hypothesis -would hold. But I mean, but it is --

NEAL R. GROSS

13

1	MR. HINNEFELD: Well, you're
2	talking uranium decay change, I don't see a
3	whole lot of change in those nine years.
4	MR. FITZGERALD: But I'm just
5	saying that that's just sort of the premise
6	here right that that would make it
7	bounding. But on the other hand
8	MR. HINNEFELD: Well, your point
9	though is that the work activities and the
10	exposures during because the activities
11	were different, you can't necessarily assume
12	that the remediation activities mimic the
13	actual operational activities as they were
14	loading that. That's the issue here. Is that
15	true?
16	DR. BUCHANAN: That's correct.
17	MR. HINNEFELD: Okay. Well,
18	unless you've got something to speak to that,
19	we'll just take it back and work on it.
20	MR. ROLFES: I was just going to
21	say just to point out, the .65 picocuries per

- 1 liter is about what you measure normally in
- 2 backgrounds.
- 3 MR. HINNEFELD: Of what?
- 4 MR. ROLFES: Radon.
- 5 MR. HINNEFELD: And that was
- 6 measured when?
- 7 MR. ROLFES: Let's see. This was
- 8 in the 1970s and '80s. The weakest was for
- 9 radon.
- 10 MR. HINNEFELD: Okay. So that's
- 11 when --
- MR. ROLFES: Yes, yes.
- 13 MR. HINNEFELD: -- Ames started
- doing some environmental monitoring around --
- 15 MR. ROLFES: Yes. Let me --
- MR. HINNEFELD: Okay.
- 17 MR. ROLFES: -- read that there.
- 18 MR. HINNEFELD: I think the issue
- here is going to be though that in '75 to '80,
- 20 these pits were sitting there and stagnant and
- 21 no one was working around it and putting

- 1 things in -- and putting materials in the 2 Is that the issue?
- 3 DR. BUCHANAN: Yes.

contained quarry.

- Okay. So the fact 4 MR. HINNEFELD: that we have environmental monitoring from a 5 6 quiet situation, the issue raised here is how 7 convince people that environmental can we monitoring from quiet situation is 8 а 9 sufficient to bound or measure the exposures two workers 10 who are actually filling I don't know what the 11 those materials now. 12 filling processes were and whether there was potential or not. 13
- 14 Ι mean, some waste pits were slurries of radioactive material that no one 15 16 got close to, and it was a liquid or a slurry 17 So you don't have a lot of exposure anyway. potential as long as you keep it under water. 18 19 But I don't know anything about that, and I don't necessarily think we need to go any 20

further to know what we need to address.

NEAL R. GROSS

21

1 DR. BUCHANAN: Okay. I'll move on 2 This is probably equal with -- is to issue 8. 3 incidents and off-normal situations. When I interviewed the workers and 4 talked to them since -- has stopped, this is 5 6 probably the biggest issue that sticks 7 their mind is that back in the '50s and early '60s, uranium was mainly viewed as a chemical 8 9 hazard, and there was debate going on. But it was mainly a chemical hazard with some minor 10 nuisance of radiation and beta activity to it. 11 12 But it was not necessarily recognized as a health hazard until later on. 13 14 And so. we're not so much concerned with the identified high activity 15 bioassay result and stuff which obviously sent 16 up a red flag under AEC was investigated I 17 18 What their concern is, is that there think. 19 were incidents that weren't recognized as being radiologically hazardous. And so, they 20

tended to the situation whether

21

it was

- 1 medical situation or whether it was a physical
- 2 or a plant situation or what. And there
- 3 wasn't any follow-up, there wasn't any
- 4 indication in the records.
- 5 And so, I went back and looked at
- 6 a few of these -- of the claims. And I looked
- 7 at their DOE files. And the couple I looked
- 8 at were fat in that they were involved in what
- 9 we consider today a serious accident with
- 10 contamination and possible intake. But their
- 11 records didn't show any attention to it other
- 12 than just what they would normally -- if they
- 13 happened to be one of the members being
- 14 bioassayed. See, they had cohort monitoring.
- 15 And so they would take a certain operational
- 16 group and they'd do bioassays -- one or two
- 17 guys would do bioassays for that group. And
- 18 then the next month, they'd have another
- 19 representative from that group.
- 20 And so if there was an incident,
- it wouldn't necessarily be caught if they had

- an intake unless there was a special bioassay.
- 2 And this did not seem to occur anyway in the
- 3 records that I looked at.
- 4 And so, I don't have a suggestion
- or a solution to this problem. And again,
- 6 it's kind of a global problem with the site is
- 7 how do you address incidents back in the
- 8 earlier days when they weren't really
- 9 recognizing radiological incidents, and so
- 10 therefore weren't necessarily entered in the
- 11 record as radiological incidents. If they
- 12 were entered in, it was more of an occurrence
- 13 -- a plant occurrence or from a medical
- 14 standpoint of view -- injuries, cuts and that
- 15 sort of thing as opposed to a radiological
- incident, especially at a production plant.
- 17 How do you address these?
- 18 And so, like I say, we don't have
- 19 an answer for it. But it is something that is
- 20 large in the claimant's mind, and it's an area
- that I can't answer them. I can't say well,

- 1 we include this in all the bioassay data
- 2 because nobody was continually bioassayed.
- 3 And so that's the way we brought up issue
- 4 number 8.
- 5 DR. MAKHIJANI: Could I supplement
- 6 that?
- 7 This has come up recently at
- 8 another site, and I'm struggling in my head to
- 9 remember which one I brought it up at. I
- 10 can't remember. But it's the issue of
- 11 blowouts.
- 12 There were pretty frequent
- 13 blowouts at Fernald. And there were also
- 14 pretty frequent blowouts where the process was
- 15 developed at Ames.
- Now at Fernald, blowouts went on
- into the '70s. That's documented. At Ames,
- 18 of course, they were quite frequent when the
- 19 process was developed. And indications are
- 20 that blowouts continue to be a problem and
- 21 maybe to a different extent at different

- 1 sites, but continue to be a problem.
- Now at Weldon Spring in the TBD,
- you said there's no record of accidents. But
- 4 I can't imagine the record of uranium
- 5 tetrafluoride reduction to metal using the
- 6 magnesium reduction process is at the sites
- 7 where there are records of accidents is that
- 8 blowouts were an issue.
- 9 And so, I think a default
- 10 assumption has to be that there were blowouts.
- 11 But I didn't see that in the literature. I'm
- 12 just supplementing what --
- 13 MR. ROLFES: Yes. We suspect that
- 14 there was. But I guess the concern would be
- whether the people that were involved in those
- incidents were bioassayed.
- 17 DR. MAKHIJANI: That's right. So
- we recognize that the bioassay record does
- 19 reflect whatever happened whether there was an
- 20 incident or not.
- 21 MR. FITZGERALD: I think it sort

1 of get into the threshold of what a bioassay -- would it be done. Portables were such that 2 it was a very high threshold. 3 It was more chemical-based than radiological-based because 4 low enriched uranium, certainly you're missing 5 6 a lot of the bioassays. And how do 7 portion that? And I'm not sure it's an easily 8 9 solvable issue because they just didn't 10 recognize enriched uranium low as а 11 radiological issue in all cases. It's 12 dilemma. of 13 Tt. sort reminds me of contamination issue. How do you do something 14 with that if you know that was the practice 15 16 and the perception, but your instances were 17 based on something other than radiological? So we know for a 18 MR. HINNEFELD: 19 fact that bioassay was a cohort monitoring scheme at Mallinckrodt? 20

NEAL R. GROSS

MR. FITZGERALD:

21

I don't think so.

- 1 I'm just saying that --
- DR. BUCHANAN: Yes, it was. Yes,
- 3 bioassay was cohort.
- 4 MR. FITZGERALD: Yes. There were
- 5 more people that were monitored. And I
- 6 believe -- it is discussed in our evaluation
- 7 report. And I'm trying to recall if they had
- 8 monitored members of each individual work
- 9 group like three times per week. I don't
- 10 recall.
- 11 Maybe Bob, on the telephone, if
- 12 you could explain. Do you recall the method
- for the little cohort bioassay sampling?
- 14 MR. MORRIS: No, I don't remember,
- 15 that, Mark.
- MR. ROLFES: Okay. I know that we
- 17 had discussed it. And I guess basically our
- 18 concern is whether a person that was involved
- in an incident would have had a bioassay is
- the bottom line. And I guess what we'll do is
- 21 take a look and see if we can find some

- indications of workers that were involved in
- 2 incidents, et cetera, and take a look at their
- 3 bioassays.
- 4 MR. FITZGERALD: Can you pull, I
- 5 guess, a small sample of just trying to --
- 6 DR. BUCHANAN: Yes. Of the actual
- 7 people I talked to and see it was in the
- 8 record.
- 9 MR. FITZGERALD: See if it was in
- 10 the record. I think --
- 11 MR. HINNEFELD: As I see your
- 12 write-up, one person's bioassay who was in
- 13 furnace fire was not -- there was no bioassay
- in his record. But something said bioassay
- 15 available in investigation report or
- 16 something? Is that what your write-up says?
- DR. BUCHANAN: No, I think it
- 18 didn't really indicate -- it didn't really
- 19 indicate that he was involved in a fire. It
- 20 says personnel monitoring summary reports --
- 21 there was another --

1	MR. ROLFES: Okay. So there's
2	DR. BUCHANAN: It's written up in
3	a MCW report. And there's information in that
4	that the dose reconstructor could use. But it
5	didn't say anything in his report that he had
6	the bioassay.
7	And the other one just had
8	something about medical aspect of the worker's
9	complaint. It didn't have anything on
10	bioassay.
11	MR. ROLFES: So this was, like,
12	you're referring to his file as, like, the DOE
13	response file didn't contain it?
14	DR. BUCHANAN: Right.
15	MR. ROLFES: Okay. Yes, that's
16	one thing that we have had in the past. Some
17	of the records don't always make it into the
18	DOE response file when they're related to an
19	incident and such.
20	And so one of the things that
21	we've done to resolve these types of issues

- 1 from our data captures from various sites --2 all the documents that are put into the Site 3 Research Database is what we can do actually search each of these documents and 4 find any kind of bioassay data or exposure 5 6 data and link those back into our NIOSH OCAS 7 claims tracking system. yes, that certainly is 8 So, 9 something important. So we want to make sure 10 that any bioassay data from an individual's incident is included in the DOE response file. 11 12 And if it isn't, we want to make sure that available to the dose 13 reconstructors during the dose reconstruction process. 14 Well, I think the 15 MR. HINNEFELD:
- 16 issue here is pretty clear though is that in 17 this instance where the person had -one there was a notation or a personal file and 18 19 there investigation report, was an 20 could go find that bioassay and do reconstruction. That's one instance where 21

- we'll find it.
- 2 But the idea, though, is if it's
- done in that fashion, how do you know you
- 4 don't miss something? How do you know you
- 5 always have that notation about data included
- 6 in an accident file?
- 7 And another important question
- 8 here is how was the cohort sampling done.
- 9 DR. BUCHANAN: And that changed.
- 10 Cohort sampling changed over time. First it
- 11 was just Fridays and then it was Monday --
- 12 Friday, Monday, Friday. And then it went --
- they changed it two or three times during the
- ten-year period if I recall right.
- MR. HINNEFELD: Okay.
- DR. BUCHANAN: Okay. So that
- 17 brings us up to issue number 9. And that is
- 18 one of the concerns of the petitioners that
- 19 qualified the ER was the geometry factor not
- 20 being included.
- 21 And so, this was important in that

1 if a person generally practiced to wear the 2 badge on the chest, and if the exposure source 3 distance term was some away, it duplicate the calibration of the badge so that 4 a reading was correct for dosimetry purposes. 5 6 However, if the source term was close or 7 further away from the badge than part of the 8 bodies, then there's a problem. Or if there was a shielding in between. 9 That's a spatial 10 issue -- a spatial and space-type issue. And if a lot of this uranium have 11 12 high theta doses -- and in fact some of them quote 20 r per hour on some of the lathe 13 And so shielding as it interfered 14 material. between the badge and the source but didn't 15 16 interfere between the source and the person's feet 17 head hands whatever the or or or situation might be, then you'd rest your dose 18 19 lower than what the person or organ received. places 20 And so а lot of that recognize this, especially using glove boxes 21

and stuff, have a geometry factor for people

2 that worked certain jobs. And of course the 3 compound disc at Weldon Spring just for 4 extremity monitoring implemented was and basically wasn't there. 5 And so there's no 6 extremity monitoring to show any extremity 7 doses that they were approximately equal to whole-body doses. If they were, then you can 8 9 say well, there's probably not too much in 10 geometry factor, but that it doesn't exist. 11 And so the geometry factor is an 12 issue here even though we haven't had claims for extremities or that sort of thing. 13 shows that from readings -- the literature on 14 their operating fields and operations that the 15 geometry factor could be important 16 in some 17 organ doses. And so, we would like to bring up the issue that geometry factors need to be 18

MR. ROLFES: Yes, I would agree with you if we had a dose reconstruction that

implemented at Weldon Spring.

NEAL R. GROSS

19

1

But I just did a quick review of 1 needed it. 2 the claims that we have in NOCTS and I didn't 3 cases where the individual their hands, for example, 4 on 5 extremity. But yes, I do agree that if a 6 situation where an individual was handling uranium materials and had recorded doses, et 7 cetera, we would certainly want to develop 8 9 some geometrical correction factors to make sure that we're accounting for the dose to the 10 extremity properly. 11 12 The other question I had was the reference you had mentioned -- the 1958 office 13 It mentioned dose rates from 10,000 to 14 memo. 35,000 millirem per hour. That doesn't sound 15 16 like uranium to me. Ι mean, that didn't 17 really sound like it was something that was from Weldon Spring Plant. 18 comina Do you recall if it was another site? 19 20 DR. BUCHANAN: No, no. This was I can give you the reference 21 -- let's see.

- 1 number for that document. That's a Weldon
- 2 Spring document. I can give you the reference
- 3 number for that.
- It was on a lathe, I think.
- 5 MR. ROLFES: All right. So it
- 6 wasn't uranium. It's likely protactinium-234
- 7 and such.
- 8 MR. HINNEFELD: Yes. If it was on
- 9 a lathe, it was probably a machine that could
- 10 surface off the --
- 11 DR. MAKHIJANI: Mark, where did
- 12 the protactinium-231 and actinium-227 come
- 13 from at Weldon Spring?
- 14 MR. HINNEFELD: That's U-235 decay
- chain. I mean, you're mainly protecting 234.
- 16 DR. MAKHIJANI: Yes. But if it's
- 17 being processed already, you expect that stuff
- 18 to have gone away, right?
- 19 MR. HINNEFELD: I don't remember
- 20 the ingrowth of those.
- DR. MAKHIJANI: They're slow.

- 1 They're very slow.
- 2 MR. HINNEFELD: Yes. It may not
- 3 be 231.
- 4 MR. ROLFES: Are you referring to
- 5 --
- 6 DR. MAKHIJANI: I just saw it in
- 7 the document you referenced.
- 8 MR. ROLFES: In the health physics
- 9 concerns for the safety materials?
- DR. MAKHIJANI: Yes.
- 11 MR. ROLFES: Okay. Yes, that
- 12 would have been a small amount from U-235
- 13 decay.
- DR. MAKHIJANI: All right.
- DR. BUCHANAN: I'll get you that
- 16 document.
- 17 MR. ROLFES: You don't have to
- 18 provide it right now. But if you could after
- 19 the meeting.
- 20 MR. FITZGERALD: But it doesn't
- 21 sound like we have a -- here either. It's

- 1 there for your -- it's a tool that you're
- 2 going to use if you need to use the tool.
- DR. BUCHANAN: Well, and it's more
- 4 though than just the extremities. It's brain
- 5 cancers and anything above the neck up and
- 6 your feeling bad doesn't necessarily reflect
- 7 it if it's coming from a lathe or something.
- 8 MR. FITZGERALD: So they're still
- 9 geometry questions.
- DR. BUCHANAN: Yes. Even though I
- 11 have a shield here and you're not -- the
- 12 brain, it could be receiving a different dose
- than the benches.
- 14 DR. MAKHIJANI: At Mallinckrodt,
- there was an also an issue of geometry where
- the source was below which applied to the
- 17 vats.
- 18 MR. HINNEFELD: Yes, there are
- 19 serious --
- DR. MAKHIJANI: And there's a --
- 21 MR. HINNEFELD: -- there's not

- 1 that -- is there? There are certain parts in
- 2 the orientations which may interest us if
- 3 needed. I'd have to go back and check on
- 4 that.
- 5 MR. FITZGERALD: So you're talking
- 6 about with maybe an analog for Weldon that may
- 7 be drawn from this.
- 8 DR. MAKHIJANI: Right. But I
- 9 think that issue was resolved.
- 10 MR. FITZGERALD: A lathe was one
- of the set-ups in the Mallinckrodt document.
- 12 A lathe was one of the set-ups.
- 13 DR. MAKHIJANI: There's quite a
- lot of very good work done --
- MR. FITZGERALD: Well, maybe a lot
- of the leg work was done on them checking out
- 17 the factories --
- 18 DR. BUCHANAN: Okay. That's the
- 19 nine issues that I had on the SEC.
- 20 CHAIRMAN GIBSON: Is everyone
- 21 clear about consulting these to further look

- into and respond back to?
- 2 MR. HINNEFELD: I took some notes.
- 3 I guess Mark probably took notes. I think
- 4 we'll -- if we have some questions -- about
- 5 what -- but I think we've got it straightened
- 6 out. And we are within written responses for
- 7 these matrix issues. Now this is clear that
- 8 this must be a summary out of a report that is
- 9 going to PA clearance or something --
- DR. BUCHANAN: Well --
- 11 MR. HINNEFELD: -- security
- 12 clearances?
- DR. BUCHANAN: It's just a draft.
- 14 It's not --
- MR. FITZGERALD: We want to slow
- 16 them up.
- 17 The report is in draft, ready to
- 18 go --
- 19 MR. HINNEFELD: That's okay.
- 20 Before you go to DoD for their security or
- 21 applications first.

- 1 MR. KATZ: So it should come out
- 2 in -
- MR. HINNEFELD: Well, I'm just
- 4 saying that normally the written reports are
- 5 very instructive about the basis behind this
- 6 number 5. That's when I'm --
- 7 DR. BUCHANAN: Yes, they'll be
- 8 more -- more details.
- 9 MR. HINNEFELD: Because I hate to
- 10 compliment the contractor -- the Board's
- 11 contractor here -- but there's a lot of well
- 12 written stuff in the actual review reports.
- 13 And the ideas usually come across pretty
- 14 clearly that the basis for the finding in some
- has been more so than just what he did in the
- 16 matrix.
- 17 MR. FITZGERALD: So that would
- take a couple of weeks that we'll be done with
- 19 this.
- 20 MR. KATZ: Well, it sounds like
- the TBD revision is also correct or at least

- 1 for a couple months.
- 2 MR. ROLFES: Correct.
- 3 MR. FITZGERALD: There's been a
- 4 couple of portions that have been in the
- 5 works, I guess. I believe the site
- 6 description has been updated. But I believe
- 7 the other significant TBDs the internal and
- 8 the external as well as the environmental dose
- 9 portions of the site profile are still in
- internal review at ORAU. And I believe we're
- 11 hoping to get those out by the end of the
- 12 year.
- 13 MR. ROLFES: And when you say out
- of ORAU or do you mean through DCAS review
- 15 too?
- MR. KATZ: I would expect that
- 17 they'd be through DCAS review too by the end
- of December -- early January.
- 19 MR. ROLFES: And will that have to
- 20 go to DOE too then?
- 21 MR. KATZ: Yes, it will.

- 1 MR. HINNEFELD: That's usually two
- weeks.
- 3 MR. KATZ: Yes. Okay. So it
- 4 sounds like that'll be out by January --
- 5 sometime in January?
- 6 MR. HINNEFELD: We'll do what we
- 7 can.
- 8 MR. KATZ: I mean, obviously it's
- 9 something --
- 10 MR. HINNEFELD: Everything we do
- is a juggling act about which fire are we
- 12 planning today or this week.
- DR. BUCHANAN: And I know that the
- 14 matrix usually comes out after the report. In
- this case, we signed that in the spring and we
- 16 didn't want to clog up the clearance pipeline
- 17 with a report --
- 18 MR. HINNEFELD: I didn't mean to
- 19 complain at all. I'm just saying that usually
- 20 the report includes really clear descriptions
- 21 --

- 1 MR. FITZGERALD: We sort of push
- the matrix out faster given schedules.
- 3 MR. HINNEFELD: I'm not
- 4 complaining. I understand.
- DR. BUCHANAN: And that reference
- 6 number on the beta dose is 14938.
- 7 MR. ROLFES: Thank you, Ron.
- 8 DR. BUCHANAN: That's a 1959
- 9 Mallinckrodt lathe operation, shielded and
- 10 unshielded.
- 11 MR. KATZ: That was an item that
- 12 you wanted a chance for someone from the ORAU
- 13 staff to come back.
- MS. HOWELL: Monica.
- 15 MR. KATZ: Monica. Early on. Is
- 16 that still open? Do we want to see if she's
- 17 back with us from her call?
- 18 MR. ROLFES: Well, I don't know.
- 19 Did we want to discuss that? That probably
- 20 falls back into the technical discussion of --
- 21 MR. HINNEFELD: If it's a

- 1 technical discussion of the timing then I
- 2 don't think we need to do it.
- 3 MR. KATZ: It was about the
- 4 pedigree of the data.
- DR. BUCHANAN: Using the ER.
- 6 MR. KATZ: So is that useful to
- 7 decide anymore?
- 8 MR. HINNEFELD: No, I don't think
- 9 so because we got to the point where the key
- 10 question was what's the origin of the exposure
- 11 history in the individual file. And if we
- have a dose reconstructor here, do you really
- 13 need that?
- 14 I've had a couple email exchanges
- 15 with ORAU, and I'm not entirely sure I
- 16 understand them. So I don't know that it's
- 17 worth talking about.
- 18 But apparently, the individual
- 19 exposure records apparently are hard copies,
- 20 records from the site. Some are handwritten.
- 21 Some are printouts from Weldon Spring

- 1 monitoring program. And those are obtained
- from Oak Ridge Operations who is the holder of
- 3 those records. So that's what shows up in the
- 4 person's file is a report that was generated
- from Weldon Spring. That's what the dose
- 6 reconstructor gets.
- 7 And it should be a little look in
- 8 on Weldon Spring's claims if not and see
- 9 exactly what's in there. It would be under
- 10 the DOE response in the claim docs. It's part
- of the documents -- claim documents.
- 12 CHAIRMAN GIBSON: Okay. Is this a
- 13 good time to break for lunch before we come
- 14 back and cover the Site Profile preliminary
- 15 responses for --
- 16 MR. HINNEFELD: I mean, it's
- 17 convenient now to break again.
- 18 CHAIRMAN GIBSON: Come back after
- 19 12:00 then?
- 20 MR. KATZ: Yes, It's noon. So
- 21 after 1:00?

1	CHAIRMAN GIBSON: Yes.
2	MR. ROLFES: Well, I think we sort
3	of discussed both of I think the Site
4	Profile issue's really been discussed in the
5	SEC evaluation portion. But I don't know how
6	much detail you want. We can certainly
7	discuss them if you
8	MR. HINNEFELD: I mean, we might
9	as well run through them. It'll take what
10	it'll take.
11	MR. ROLFES: Sure.
12	DR. MAURO: This is John. Real
13	quick before you break, I just wanted to check
14	with you this paper by Adams and Strom in
15	Health Physics on DWEs. I'd like to ask do we
16	get the green light to go ahead and look into
17	that and perhaps write up a white paper on it?
18	MR. KATZ: Yes. It may not
19	require a white paper out of this. But
20	certainly take a look at it and see
21	DR. MAURO: Okav. We'll take a

- 1 look at it and be prepared just to report
- 2 back. And certainly the work group could then
- decide whether it'd like a white paper or not
- 4 depending on the complexity.
- DR. MAKHIJANI: John, let me
- 6 suggest that what we might do is compare
- 7 what's in that paper with what we did before
- 8 and write a short memo on that. It might be
- 9 as simple as that. Or it might need a white
- 10 paper. I don't know.
- DR. MAURO: Right. Well, I'd like
- 12 to also look at what's in that paper and what
- 13 actually done for example on a number of
- 14 places where DWEs were used in the past and
- 15 whether or not that -- let's say we find that
- 16 protocol reasonable in Adams, and then we'll
- 17 see whether or not that protocol was in fact
- 18 employed in many of the cases that we've
- 19 reviewed in the past.
- 20 MR. KATZ: Yes. And John, the
- 21 only thing I'm feeling a little uncertain

- about is DCAS has part of this equation too to
- 2 explain how that paper or its methodology sort
- of relates. And until you have that, you may
- 4 not be able to respond fully on this issue.
- 5 DR. MAURO: Yes. I think I'd just
- 6 like to do a little homework to see what was
- 7 done.
- 8 MR. KATZ: Absolutely.
- 9 DR. MAURO: And you know why?
- 10 Because it's going to come up again on Fernald
- 11 real soon. And the more we know about it, the
- more intelligently we can speak about it.
- 13 MR. KATZ: Sure. But absolutely
- 14 you can dig into it.
- DR. MAURO: Okay. But we'll keep
- it light just enough so we get familiar with
- 17 it.
- 18 CHAIRMAN GIBSON: Well, I quess I
- 19 have no idea how much their work -- Mark,
- 20 what's your sense as to how much is there to
- 21 go through with TBD review that hasn't been

- MR. KATZ: Well, we've sort of
- 3 hinted on some of these things. If you look
- 4 at issue number 1, we've discussed atmospheric
- 5 monitoring data for the operational period.
- 6 And basically, many of these responses were
- 7 basically saying that we're updating the Site
- 8 Profile, and that should be coming out at the
- 9 end of this year.
- 10 We might be able to run through
- 11 these in 15 minutes possibly.
- 12 MR. HINNEFELD: It's okay with me.
- 13 CHAIRMAN GIBSON: We'll take a
- 14 quick break, make sure we've got everyone
- 15 still on the phone and then just --
- MR. KATZ: Yes. You want to take
- 17 a ten-minute break and then come back and
- 18 we'll try to knock this off about half past
- 19 the hour or so?
- It may be useful, Mark, because it
- 21 may help you in your final review of the TBD

- 1 to hear whatever -- okay. So in ten minutes,
- 2 yes?
- 3 MEMBER LEMEN: Does that mean
- 4 you're not going to take a lunch break and
- 5 you're just going to try and finish the whole
- 6 agenda and then --
- 7 MR. KATZ: I think so. We're
- 8 going to try to do that. So if we find that
- 9 it takes longer, we'll break at 12:30 for
- 10 lunch.
- 11 MEMBER LEMEN: If we can finish
- the agenda, then we'd be done.
- 13 MR. KATZ: Then we would be done
- 14 for the day. Yes.
- The only other thing we have to
- 16 talk about is possibly scheduling the next
- one.
- 18 MEMBER LEMEN: Okay. I just
- 19 wanted to -- never mind. I'll just wait until
- 20 I get back.
- 21 MR. KATZ: Okay. Thanks.

1 (Whereupon, the above-entitled 2 matter went off the record at 12:02 p.m. and 3 resumed at 12:14 p.m.) 4 MR. KATZ: Okay. We are 5 reconvening after a short break. We're going 6 to try to wrap things up. I think we can do 7 pretty quickly because Mark during the break looked at the TBD review responses and 8 9 found that a lot of this has been discussed. 10 ROLFES: Yes, I think we've MR. been discussing these issues really as part of 11 12 the SEC discussion that we had earlier. Just to go through some of these, 13 the first issue on the NIOSH responses 14 review of the Weldon 15 SC&A's Spring Site Profile, we had discussed the lack -- well, 16 17 SC&A found that there lack of was а monitoring 18 environmental data for the 19 operational period. We now have more robust And we've listed reports from 20 perimeter data. which we environmental monitoring 21 got the

- data. I don't know if we need to discuss that
- 2 any further.
- MR. HINNEFELD: Well, not in terms
- 4 of that. There's still the main issue of
- 5 back-extrapolation using the plume model on
- 6 the site. That's still something that needs
- 7 to be talked about.
- 8 MR. ROLFES: Okay. All right.
- 9 Let's see. Number 2, I think we have --
- 10 special data for unmonitored workers internal
- 11 environmental dose. That's essentially
- 12 addressed in number 1 as well.
- 13 And number 3, lack of validation
- 14 for maximum environmental dose, we've once
- 15 again pointed back to our response to item 1
- 16 and have mentioned the additional
- 17 environmental monitoring data from Weldon
- 18 Spring Plant environmental monitoring reports.
- 19 Let's see. Now if we take a look
- 20 at number 4, basically SC&A has identified
- 21 that there's an incomplete assessment of

1 uranium decay products. And taking a look at 2 what's presented here -- let's see -- I think 3 if you look at the last paragraph of our here, it NIOSH intends 4 response says, to revise the TBD to include contributions of 5 6 thorium-230, -232 and decay products which are 7 more important to internal dose. So this is 8 something that we have agreed with you and 9 have decided to update our Site Profile. And 10 so that should be incorporated in the December revisions of Weldon Spring Site Profile. 11 12 DR. BUCHANAN: Ouestion. I have a question on number 4, the last sentence there. 13 It says, change will only be appropriate with 14 intakes before initial processing. 15 16 MR. ROLFES: Yes. Okav. The 17 initial processing of materials would separate 18 the thorium from the uranium. So that's --19 DR. BUCHANAN: At what point would How are you going to determine that 20 that be? in dose reconstruction? Ιf 21 а person was

exposed to the whole chain or the purified chain?

Well, usually if you MR. ROLFES: dose actually take look the а at reconstruction methods that we use, if you are interpreting an individual's bioassay data for uranium, you convert that mass quantity into a specific -- into an activity that is excreted in a 24-hour time period. If you assume that all of that activity resulted from different. U = 234rather than all of the isotopes that make up natural uranium, always going to be higher for dose is majority of the organs. I think there might be one or two organs where considering another issue, the internal dose could be slightly elevated.

But the bottom line is when you assume that all of the internal dose from uranium results from U-234 rather than a distribution of U-234, U-235, U-238, the U-234

NEAL R. GROSS

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

- 1 internal dose is always going to be greater 2 and more claimant-favorable. And that's the 3 method that we use in dose reconstruction. 4 So I think that your concern about thorium-234, if we would evaluate thorium-234 5 6 intakes, if we would look at the individual 7 components -- the isotopic make-up of what the 8 individual exposed the actual was to 9 internal dose that we would calculate would 10 likely be lower than what we would do in our 11 dose reconstructions now. 12 DR. BUCHANAN: Well, my question what do mean by that 13 is you These changes will only be half of 14 sentence.
- you explain what that sentence means?

 MR. ROLFES: Well, I think I
 mentioned it would be the -- let me see, let
 me read through this entire -- so the ratios

the intakes before initial processing.

21 really only be concerned about the thorium-

versus

the U-234,

of thorium-230

15

20

we

Can

- 1 230.
- MR. HINNEFELD: Well, I mean what
- 3 that sentence says is that after you would
- find it, then that stuff's gone. And that's
- 5 what that sentence says. And your question is
- 6 beginning new dose reconstruction, how do you
- 7 know if this guy was exposed before or if it
- 8 was afterwards.
- 9 So we'll have to take a look at
- 10 what exactly is intended on that response.
- 11 I'm having a little trouble following it
- 12 myself.
- DR. BUCHANAN: Okay.
- 14 DR. MAURO: This is John. I have
- 15 a question.
- Now we're dealing with
- 17 concentrates where the material predominantly
- is the naturally occurring isotopes slightly
- 19 enriched slightly enriched -- the two percent
- 20 -- which would include the thorium-234
- 21 protactinium, and of course uranium-234. But

- 1 you wouldn't have very much thorium-230 or
- 2 radium-226, right?
- DR. MAKHIJANI: No.
- DR. MAURO: So I quess the
- 5 question I have for Ron, are you concerned how
- they're going to deal with the internal doses
- 7 to thorium-230 and radium-226? Or did the
- 8 question go toward more the short-lived
- 9 progeny of the 238?
- DR. BUCHANAN: I'd have to go back
- 11 and re-read the whole thing again. But I
- 12 remember that the inhaled thorium-234 was not
- included from the decay of the material in the
- 14 person's body itself.
- 15 DR. MAURO: Okay. Yes. When you
- do the internal dose from 238 -- this goes to
- 17 IMBA, I guess -- I believe the thorium-234
- ingrowth and the protactinium, that's all part
- 19 of it.
- 20 Well, I'm drawing a little bit of
- 21 a blank now, but --

Well. 1 MR. HINNEFELD: Yes. the response here is that what we wrote is that 2 3 the protactinium-234 the thorium-234 and intakes are small contributors to the dose. 4 a routine practice, what we do at 5 And as uranium intake, we assume all the uranium 6 7 activity is thorium-234. Uranium-234. And so 8 which gives you more dose per amount 9 inhaled than uranium-238. And by doing that, 10 you've covered essentially not only U-238 but also those intervenings short- and half-life 11 12 daughters. I would agree 13 DR. MAURO: Yes. with you completely that --14 MR. HINNEFELD: That's the first 15 16 part of the response then. 17 DR. MAURO: Yes. 18 The second part of MR. HINNEFELD: the response gets into thorium-230 and 232 --19 20 DR. MAURO: Okay. 21 HINNEFELD: their MR. and

1	presence	in	the	concentrates.
_	PICDCIICC		$c_{11}c$	COLICCITCE acces.

2	And what we say in our response is
3	that we're going to revise it to take those
4	into account that those will only be
5	applicable to intakes before initial
6	processing. While that's technically true, as
7	a practical matter, it's not clear that we'll
8	know when we do a dose reconstruction whether
9	somebody's exposure was to pre-refined or
10	post-refined uranium. And so why even make
11	the distinction? I mean, to me, it's not
12	going to be a lot.

- DR. MAKHIJANI: It's a small thing.
- MR. HINNEFELD: Yes. So I think
 we understand the whole thing. It's just
 we've got to clarify exactly where we're going
 with the response here.
- I don't know that this response
 which has to do with the technical feasibility
 of doing dose reconstruction and the way that

- you would theoretically do a dose reconstruction translates real well into how actually dose reconstruction is going to be done. So that's the thing we need to think about on our part of this response.
- 6 ROLFES: All right. Looking MR. 7 5, discussed the on at issue we radon I don't know if we need to discuss 8 exposure. 9 this any further. But we did discuss with. 10 method coming that we are up We 11 discussed our radon source term and our 12 assumptions for employee exposure. I think we've agreed that we would take a look at that 13 again as well. 14
- Let's see. If we move on to 6,

 the issue here was the different solubility

 classes listed for the same element. This is

 really a dose reconstruction issue.
- And what NIOSH does when we complete a dose reconstruction, we would use the chemical solubility for the given nuclide

- which resulted in the highest internal dose to
- the target organ in the dose reconstruction.
- 3 So it's a matter of assumption that is
- 4 claimant-favorable.
- 5 Should we move on?
- 6 Okay. Number 7, missed dose and
- 7 co-worker data not adequately addressed. Our
- 8 response here is that the TBD did not have a
- 9 formal co-worker study in it. However, the
- 10 urine data summarized in Tables V-8 through V-
- 11 17 may be used by dose reconstructors to
- 12 estimate the doses if an employee's records
- are not available for a given time period.
- 14 And the data included part of the
- median and 95th percentiles.
- DR. BUCHANAN: Yes. That kind of
- 17 goes back to our original verification of data
- 18 and stuff.
- 19 Now I did have a question on the
- 20 MDA. It wasn't really clear on page 18 of TBD
- 5 exactly how it was decided upon to use that

1 MDA value. Maybe that was page 18.

some discussions made 2 There were on the bottom of page 17. And then it was 3 said that the .008 milligrams per liter was 4 derived from Rocky Flats and supported for use 5 6 at Weldon Spring. And so, to me, that's not 7 quite a lot of support for it. If we're going to use .008 milligrams per liter at Weldon 8 9 Spring, is there any other we way 10 substantiate that rather than well, say used it at Rocky Flats? 11 That was the way I 12 understood it. If there's a different work for that, if I could hear it --13

MR. ROLFES: All right. Yes, we can certainly look at the MDA.

Let's see. Yes, we didn't address that I don't believe in our responses. But that's something we'll look at -- the limit of detection for the uranium bioassay. And we can take a look back and see if they reported any less than values for example.

NEAL R. GROSS

16

17

18

19

20

21

1 But the fluorometric method that
was used; it was pretty common and we can
3 probably come up with a good estimate based or
4 other sites that were doing the same
operations in the same time period.
6 DR. BUCHANAN: I would think as
7 thorough as Mason was and he was there at
8 that time that he would have said something
9 somewhere about that detected limit because he
10 was pretty thorough.
DR. MAKHIJANI: And this also
brings up the Mason comment in the mid-70s.
13 And I think you have that document. Ron, did
14 you send that document to Mark? I think NIOSE
15 has that document
MR. KATZ: Yes.
DR. MAKHIJANI: where there was
18 this objection that bioassay data was never
19 meant to be used for dose reconstruction.
20 And this has come up before. And
21 I think and I actually addressed this by

- 1 saying using new models and reinterpreting old
- 2 data.
- 3 But the thing that was different
- 4 that struck me about this memo -- just to call
- 5 your attention to it -- was that it was
- 6 written in the mid-70s when the methods were
- 7 already more developed and as a retrospective
- 8 on what happened at Mallinckrodt by Mason.
- 9 And I think it's worth another re-look and a
- 10 response -- well, since a petitioner has
- 11 raised it.
- 12 MR. ROLFES: Okay. What was the
- issue? I'm sorry.
- 14 DR. MAKHIJANI: The issue was that
- 15 bioassay data was never collected for dose
- 16 reconstruction.
- 17 MR. ROLFES: Okay. Yes, I mean,
- 18 just explain that I don't have the document in
- 19 front of me at this moment. But I did look at
- 20 it a couple weeks back. And I suspect that
- 21 this issue is related to the unavailability of

- 1 the biokinetic models to --
- DR. MAKHIJANI: Right.
- 3 MR. ROLFES: -- interpret bioassay
- 4 data.
- DR. MAKHIJANI: I agree. And I
- 6 know that NIOSH has addressed this before.
- 7 But since it came up explicitly from the
- 8 petitioner -- and I guess I should have
- 9 remembered to bring it up in our prior
- 10 discussion -- but since we're discussing
- 11 uranium right now, I remembered it and
- 12 forgotten all morning. It might be worth just
- if you feel the same response is valid since
- 14 this came up explicitly.
- MR. ROLFES: Okay. Sure.
- 16 Shall we move on to 8? This is
- 17 related to shallow and extremity doses. And
- 18 let's see. I'm looking at the review of the
- 19 -- I don't know if you want to introduce this,
- 20 Ron, or not. But I think we've already
- 21 touched on the geometrical correction factors

- 1 you had previously mentioned.
- DR. BUCHANAN: Yes.
- 3 We have no extremity MR. ROLFES: time monitoring data for the period 4 5 Weldon Spring was operating. But then again 6 don't have right for we any cases now 7 individuals that were handling uranium that 8 had skin for example, cancer, an 9 extremity like for example their hand was the 10 specific search that I had done, or 11 forearm. But we do agree that if a case comes 12 where need a geometrical correction we 13 factor or an extremity, then we would certainly look at that issue. 14

far as the other organs, you had mentioned the head or lower torso, for example. You'd have to take a look at dosimeter position. And I think Stu had said that this was more of a generic issue that multiple sites rather spanned than one specific site.

NEAL R. GROSS

15

16

17

18

19

20

21

1 MR. HINNEFELD: Yes. What we 2 should do is take a look at the Mallinckrodt 3 because I'm quite -- about the use of geometry We should take a look at that and see 4 models. how we feel about that or something similar to 5 6 that. 7 You might consider DR. MAKHIJANI: generalizing it. 8 9 Yes. Exactly. MR. HINNEFELD: 10 Right. Well, beyond the 11 DR. MAKHIJANI: 12 geometry question, the skin piece of that is And the geometry less a geometry question. 13 question is that deep dose where the badge 14 15 was, the organ. The skin dose question is a little 16 more difficult. I was telling Stu off line 17 it might be worth -- I mean, this has 18 19 come up a number of times also. And it might the Bethlehem 20 be worth looking at Steel discussions where this came up first in our 21

- 1 review process. There's quite a lot that was
- done. I mean, there's an item in the exposure
- 3 matrix I just checked. I don't remember all
- 4 of the discussion that led up to that item
- 5 being in the exposure matrix. But I think
- 6 with uranium -- and we've got to assume that
- 7 uranium was handled at Weldon Spring because
- 8 all of this was metal, right? And so people
- 9 were handling it.
- 10 And so, even though you don't have
- 11 wrist-to-ring dosimeters, you have to
- 12 calculate it --
- 13 MR. ROLFES: Sure. I can work
- 14 with -- but I'm not sure what the issue that
- 15 you're --
- MR. HINNEFELD: What he's saying
- 17 right now is --
- 18 DR. MAKHIJANI: The literature
- 19 available to you that you can refer to.
- 20 MR. HINNEFELD: The issue of what
- 21 we were talking about working with uranium and

- 1 not having egress monitoring and what do you
- 2 do in a situation like that has been addressed
- and apparently resolved in Bethlehem Steel is
- 4 what he's saying.
- 5 MR. ROLFES: Oh, okay.
- 6 MR. HINNEFELD: So we can look at
- 7 Bethlehem Steel for ideas on how to deal with
- 8 it.
- DR. MAKHIJANI: Just trying to be
- 10 helpful.
- 11 MR. ROLFES: It's really the
- 12 contamination --
- MR. HINNEFELD: You were acting so
- out of character, we didn't recognize you.
- 15 (Laughter.)
- DR. MAKHIJANI: It's totally in
- 17 character. You just don't know my character.
- 18 MR. ROLFES: Just to make sure
- 19 we're on the same page, you're relating your
- 20 concern about skin contamination rather than
- 21 the shallow dose from a direct radiation

- 1 source.
- 2 MR. HINNEFELD: Yes. We should
- 3 just go into Bethlehem Steel and see what it
- 4 says. I think it would be helpful for the
- 5 discussion.
- DR. MAKHIJANI: It would. I was
- 7 part of that discussion.
- 8 MR. ROLFES: Okay. Issue 9, we
- 9 have the badging policy was not consistent.
- 10 And let's see. I don't know if you want to
- 11 introduce this, Ron. Yes, we have quite a
- 12 large response.
- DR. BUCHANAN: Yes, our main
- 14 emphasis there is that yes, the operators were
- 15 badged, and we know that. But there are
- 16 people probably would have been badged today
- that weren't badged back in those days.
- 18 And so, my concern is that how is
- 19 the dose reconstructor going to know whether
- 20 to assign them environmental external dose or
- 21 some form of operator dose. And this is

1 problematic in that if you look at the 2 workers' records, they don't really say where they worked very explicitly as a function of 3 time. They may be assigned to a certain 4 5 department or a division or even a building. 6 But that doesn't necessarily mean that the guy 7 mowed the lawn or he stayed in that area. He 8 could have been around any of this. 9 So as far as badging, not so much 10 that the workers were badged as opposed to the other workers that weren't badged. 11 How do we 12 know they shouldn't have been badged certain times and certain instances? 13 how are we going to sort out the difference 14 15 between people that should just receive should 16 environmental dose and those that

MR. ROLFES: Again, that's certainly something that's important if an individual is monitored but appears to have

NEAL R. GROSS

receive say 50 percent of the operator's dose

or something?

17

18

- 1 had a potential for exposure. We certainly
- 2 would assign an unmonitored dose to that
- 3 employee. However, if we had indication that
- 4 that individual had never entered into a
- 5 production area or an area where they were
- 6 storing radioactive materials, I would think
- 7 that the ambient exposures would certainly be
- 8 the more appropriate.
- 9 Let's see.
- 10 DR. MAKHIJANI: Can I ask an
- 11 information question? What fraction of the
- 12 workers were routinely badged at Weldon
- 13 Spring? Just order of magnitude.
- DR. BUCHANAN: About half.
- MR. ROLFES: I was going to pull
- 16 up our evaluation report and give you an idea
- of the external monitoring data here. I know
- it's answered in there.
- DR. MAKHIJANI: That's a lot less
- 20 than at other sites --
- DR. BUCHANAN: Yes.

- DR. MAKHIJANI: -- typically for
- 2 the period.
- DR. BUCHANAN: Right. The
- 4 probable correct answer is about half.
- 5 MR. ROLFES: I'm hunting through
- 6 the document at this --
- 7 DR. MAKHIJANI: Well, I'll find
- 8 out. It's fine. I have the answer I need.
- 9 DR. BUCHANAN: It wasn't the kind
- of -- where everybody walked through the cave
- 11 that day.
- DR. MAKHIJANI: Right.
- MR. ROLFES: Right. I'm not
- 14 seeing it. Did you want me to continue to
- 15 look for it?
- DR. MAKHIJANI: No, no. I can
- 17 find it. I have the answer.
- 18 MR. ROLFES: Okay. Did we discuss
- 19 that, or is there anything else that you
- 20 needed clarification and/or a response on?
- 21 MR. HINNEFELD: For this one,

- 1 since it's such a long response, I would like
- 2 SC&A to let us know if there are still
- 3 questions after they've gone through the
- 4 response.
- 5 MR. ROLFES: Sure.
- 6 MR. HINNEFELD: Okay?
- 7 DR. BUCHANAN: Yes. We haven't
- 8 had time. I got this Friday.
- 9 MR. HINNEFELD: This one came out
- 10 a little bit ago.
- 11 MR. ROLFES: Okay. And the final
- 12 issue that we had in here is lack of
- 13 sufficient co-worker data development for
- 14 external dosage. It essentially is part of
- 15 the previous question that was had.
- DR. MAKHIJANI: That was the
- 17 reason for my question. We established that.
- 18 MR. ROLFES: Okay. What we've
- 19 identified in our evaluation report was that
- there were 8,000 external monitoring records
- in the CER database representing 1,850

- employees during the period from 1957 through
- 2 1967.
- 3 DR. MAKHIJANI: So the whole
- 4 question of the CER database that we talked
- 5 about in the morning becomes a lot more
- 6 important.
- 7 MR. ROLFES: Okay. I think that
- 8 covers the Site Profile Review matrix.
- 9 Is there anything else that we
- 10 need to discuss?
- 11 DR. BUCHANAN: There were 28
- 12 findings in Site Profile.
- MR. ROLFES: Okay. I know that we
- 14 didn't receive a matrix from SC&A. So for
- this meeting in advance of it, we prepared
- 16 what we felt were the issues of concern. And
- 17 so we tried to lump some of them into --
- 18 MR. HINNEFELD: Into those ten.
- MR. ROLFES: Right.
- 20 (Laughter.)
- 21 MR. ROLFES: I know one of the

- issues that wasn't included in this matrix was
- the recycled uranium issue. However, we did
- 3 previously discuss that as part of the SEC
- 4 evaluation.
- 5 So I don't know if there's other
- 6 things that we did not address. If there's
- 7 other issues that you've identified that we
- 8 haven't really discussed or at least
- 9 understood better, then we'd certainly --
- DR. BUCHANAN: I haven't had time,
- of course. Like I say, I got this Friday at
- 12 noon. I haven't had time to go back and look
- 13 at this and see if it covers any update --
- 14 lumped them all in for --
- 15 MR. FITZGERALD: Maybe that's an
- 16 action that we should take just to come back
- and look at later. You've listed the primary
- 18 ones. Whether there's any others that you
- 19 haven't set as primary.
- 20 MR. KATZ: Right. If there are,
- 21 you can just add them to this document.

MR. FITZGERALD: Sort of avoid the duplication? DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	1	DR. MAKHIJANI: Could I make a
Since we have two matrices going on the same site that the issues that we think are SEC issues be at the top and the issues that are residual be in the same matrix. Then if we resolve SEC issues and agree that they're separate issues, then you can just note that and work from one matrix. MR. FITZGERALD: Sort of avoid the duplication? DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	2	process suggestion that worked quite well at
on the same site that the issues that we think are SEC issues be at the top and the issues that are residual be in the same matrix. Then if we resolve SEC issues and agree that they're separate issues, then you can just note that and work from one matrix. MR. FITZGERALD: Sort of avoid the duplication? DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	3	Hanford?
that are residual be in the same matrix. Then if we resolve SEC issues and agree that they're separate issues, then you can just note that and work from one matrix. MR. FITZGERALD: Sort of avoid the duplication? DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	4	Since we have two matrices going
that are residual be in the same matrix. Then if we resolve SEC issues and agree that they're separate issues, then you can just note that and work from one matrix. MR. FITZGERALD: Sort of avoid the duplication? DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	5	on the same site that the issues that we think
if we resolve SEC issues and agree that they're separate issues, then you can just note that and work from one matrix. MR. FITZGERALD: Sort of avoid the duplication? DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	6	are SEC issues be at the top and the issues
9 they're separate issues, then you can just 10 note that and work from one matrix. 11 MR. FITZGERALD: Sort of avoid the 12 duplication? 13 DR. MAKHIJANI: Yes. And then we 14 can go back to our Site Profile and kind of 15 bend those 22 and make a reference to those 16 findings in this new consolidated matrix. It 17 might make it easier. 18 MR. KATZ: So does SC&A want to 19 merge these matrices and make a spreadsheet? 20 DR. MAKHIJANI: It might be	7	that are residual be in the same matrix. Then
note that and work from one matrix. MR. FITZGERALD: Sort of avoid the duplication? DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	8	if we resolve SEC issues and agree that
MR. FITZGERALD: Sort of avoid the duplication? DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	9	they're separate issues, then you can just
DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	10	note that and work from one matrix.
DR. MAKHIJANI: Yes. And then we can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	11	MR. FITZGERALD: Sort of avoid the
can go back to our Site Profile and kind of bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	12	duplication?
bend those 22 and make a reference to those findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	13	DR. MAKHIJANI: Yes. And then we
findings in this new consolidated matrix. It might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	14	can go back to our Site Profile and kind of
might make it easier. MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	15	bend those 22 and make a reference to those
MR. KATZ: So does SC&A want to merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	16	findings in this new consolidated matrix. It
merge these matrices and make a spreadsheet? DR. MAKHIJANI: It might be	17	might make it easier.
DR. MAKHIJANI: It might be	18	MR. KATZ: So does SC&A want to
	19	merge these matrices and make a spreadsheet?
21 useful.	20	DR. MAKHIJANI: It might be
	21	useful.

- 1 MR. FITZGERALD: Yes, we'll draft
- them and bring them back a lot earlier before
- 3 the next meeting. That way you can read it
- 4 and see if you agree with it or not.
- 5 MR. HINNEFELD: Do you want to use
- the one that we assembled as a starting point?
- 7 Or do you want to start with the 28 that you
- 8 wrote and sort of match up what these may
- 9 address or we should address?
- 10 Well, there are two reasons I ask
- 11 that. You can use this one. Fine. But we
- should probably get you a Word version of it
- as opposed to a PDF version of it based on my
- 14 experience.
- 15 Can we do that for him -- get a
- 16 Word version of it?
- 17 MR. ROLFES: Yes. Certainly.
- 18 MR. FITZGERALD: If you want to
- 19 just take a look and decide -- I'm not
- 20 familiar enough with the 28.
- 21 MR. HINNEFELD: It's something to

- 1 think about going forward.
- 2 MR. FITZGERALD: -- which way you
- 3 want to start.
- DR. BUCHANAN: Well, if you'll
- send me a Word version of this, and what I'll
- do is I'll go in and I'll take our 28 issues
- 7 and somehow put this in with that. These are
- 8 the ones that we didn't answer.
- 9 MR. HINNEFELD: If for nothing
- 10 else, send us the 28, and we'll cross out
- which ones we think are addressed in number 1
- 12 response or something because we're the ones
- who did that. Or there may be some that are
- 14 not responded to.
- 15 MR. KATZ: Well, going back to
- 16 Arjun's suggestion too, I mean, I think
- obviously a lot of these will go into the SEC
- 18 portion of it. So just that meld will go into
- 19 the new matrix.
- DR. BUCHANAN: I can redo the Site
- 21 Profile issue with the SEC's up front --

- listed first, and then list the other 28 --
- 2 remaining 28.
- MR. HINNEFELD: If they remain 28.
- DR. BUCHANAN: Yes. They'll be --
- 5 MR. HINNEFELD: Some of the
- findings for review may be considered SEC.
- 7 MR. ROLFES: Well, it made sense
- 8 to merge them but that's what they've done and
- 9 that makes the conversation simpler if they're
- 10 merged.
- 11 But we're coming out with one
- 12 matrix, not two.
- DR. BUCHANAN: Okay. And once I
- do that, do you want me to send it to you and
- 15 you say okay, I answered these in here? Or do
- 16 you want me to take this and put it into my
- 17 matrix and say this is for the answers --
- 18 MR. HINNEFELD: Well, I'd kind of
- 19 leave it to your discretion probably. And
- 20 probably whatever works for you. You're
- 21 assembling this matrix. Whatever works for

- 1 you whether you want to use the 28 original or
- the 10 that we feel like we kind of summarized
- 3 the 28 into -- whichever works for you. If
- 4 you use the 28, we'll take a look and we'll
- 5 see which one we think -- the three --
- 6 MR. FITZGERALD: Yes, with the
- 7 admonition I think if we can simplify it by
- 8 consolidation, then it would make more sense
- 9 to have fewer than that.
- DR. BUCHANAN: If you'll send me
- 11 and --
- 12 MR. HINNEFELD: I don't have a
- 13 Word file of it.
- 14 MR. FITZGERALD: Yes, I have the
- 15 Word file.
- MR. HINNEFELD: Okay.
- 17 DR. MAKHIJANI: Maybe since you
- 18 know which of the 28 were merged if you could
- indicate that to Ron, it would make the job a
- 20 lot easier.
- 21 MR. HINNEFELD: Yes. Can you do

- 1 that at this point, do you think?
- 2 MR. ROLFES: I'd certainly ask
- ORAU to do that since they're the ones that
- 4 prepared this from the SC&A's review.
- DR. BUCHANAN: If they merge some
- 6 of them --
- 7 MR. HINNEFELD: Talk to -- make
- 8 sure they don't an additional some sort of
- 9 tasking --
- 10 MR. ROLFES: Right. There may
- 11 have been something for example like the
- 12 recycled uranium issue we discussed as an SEC
- 13 issue that --
- MR. HINNEFELD: Okay.
- 15 CHAIRMAN GIBSON: Okay. Do we
- 16 want to hunt for a date now or do we want to
- 17 at least get a time frame and how long is this
- 18 going to take?
- 19 DR. MAKHIJANI: Seems like late
- 20 January is --
- 21 MR. HINNEFELD: Yes. It sounds

- 1 like at least the evaluation report revision
- will be available in late January.
- I hate to make schedule
- 4 predictions very precisely in these meetings
- 5 because there are a lot of things that go into
- 6 what happens on a schedule between now and
- 7 January.
- 8 CHAIRMAN GIBSON: Well, couldn't
- 9 you just plan on late January? If you guys
- 10 just keep me in the loop be it email then
- 11 maybe after the first of the year we can start
- 12 tossing around some dates or something. Does
- 13 that sound right?
- 14 MR. HINNEFELD: Yes. I think for
- my purposes if I'm to be here, late January
- 16 would be the preference rather than getting
- 17 into February. I'm going to be on vacation
- 18 for most of February until the Board meeting.
- MR. KATZ: So why don't we just go
- ahead and grab a date for now? We can change
- 21 it.

- 1 MR. HINNEFELD: Sure. Can we make
- 2 it tentative or something?
- 3 MR. KATZ: But why don't we pick a
- 4 date while we can?
- 5 Like in the last week of January
- 6 which in my look is clear.
- 7 MR. HINNEFELD: Yes, I'm good that
- whole week.
- 9 MR. KATZ: Dick, are you still
- 10 with us?
- 11 MEMBER LEMEN: Yes, I am.
- 12 MR. KATZ: So how's, for example,
- the middle of the week -- the 26th of January
- 14 -- on your calendar?
- 15 MEMBER LEMEN: Twenty-sixth? I
- 16 would prefer the 25th. The 26th is kind of
- 17 heavy. But I can probably switch things
- 18 around.
- 19 MR. KATZ: The 25th? That makes
- 20 no difference.
- 21 MR. HINNEFELD: It makes no

- difference to me.
- 2 Mark, you got a --
- 3 MR. ROLFES: The 25th? I don't
- 4 believe I have any -- let me make sure. I'll
- 5 be silent and let you know if I have a problem
- 6 as soon as I can get back into my calendar
- 7 here.
- 8 The 25th is Tuesday? That works
- 9 for me.
- 10 MR. KATZ: Okay. Let's just set
- 11 that as a tentative. Right now, we'll have
- 12 that as a date. If we need to change it,
- we'll change it down the road.
- 14 MEMBER LEMEN: The 25th, right?
- 15 MR. KATZ: The 25th of January.
- And that would be another meeting here face to
- 17 face.
- 18 DR. MAKHIJANI: I'll have to
- 19 participate by phone probably. But that'll be
- 20 just fine. I don't have a problem. That's
- 21 fine.

1	CHAIRMAN GIBSON: Okay. And just
2	one more thing before we close out.
3	If there's anyone on the line
4	any claimants or petitioners that have any
5	comments or questions about today's meeting or
6	anything that we could potentially address in
7	the future, we'd like to open the floor and
8	hear from you now.
9	Any claimants or petitioners who
10	would like to make a comment?
11	(No response.)
12	Okay.
13	MR. KATZ: Okay. Thank you, Mike.
14	MR. ROLFES: The one other thing,
15	are we going to exchange emails about what
16	we've agreed to do sometime in
17	MR. HINNEFELD: Yes. You should
18	put together your patch-on list. You send it
19	to Ted and the work group members and then the
20	
21	MR. KATZ: Right. SC&A will do

1	the same.
2	MR. HINNEFELD: And copy Emily.
3	MR. ROLFES: Okay. Great.
4	MR. KATZ: And we're adjourned?
5	CHAIRMAN GIBSON: Yes.
6	MR. KATZ: We're adjourned
7	Thanks.
8	(Whereupon, the above entitled
9	matter went off the record at 12:47 p.m.)
10	
11	
12	
13	
14	
15	
16	
17	